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2017	 The	 South	African	 Society	 for	 Basic	 and	 Clinical	 Pharmacology	 Conference	 held	 at	 the	
University	of	the	Free	State	(Department	of	Pharmacology),	Bloemfontein	on	1–4	October	



















combination.	 This	 event	 emphasizes	 the	 need	 for	 ongoing	 development	 of	 new	 and	
effective	drug	combinations.		
This	 research	 aimed	 to	 identify	 efficacious	 combinations	 selected	 from	 a	 group	 of	
compounds	 known	 to	 induce	 oxidative	 stress	 by	 redox	 cycling	 combined	 with	 an	
artemisinin,	 which	 as	 an	 oxidant	 drug	 also	 induces	 oxidative	 stress	 but	 is	 unable	 to	
undergo	redox	cycling.	Combination	of	the	artemisinin	with	a	redox-active	compound	is	
expected	to	both	enhance	and	maintain	oxidative	stress	within	the	parasite’s	proliferative	
environment.	 These	 combinations	 should	 be	 used	 together	 with	 a	 third	 drug	 with	 a	
completely	different	mode	of	action,	such	as	a	quinolone.		
Selected	 amino	 artemisinins	 and	 redox	 active	 phenothiazines,	 phenoxazines,	








In	 vivo	 pharmacokinetic	 (PK)	 profiling	 was	 also	 carried	 out	 by	 intravenous	 and	 oral	
administration	of	the	individual	compounds	to	healthy	C57BL/6	mice.	Biological	samples	
were	 analysed	 via	 liquid	 chromatography-tandem	 mass	 spectrometry	 (LC-MS/MS)	
bioanalytical	 methods,	 which	 were	 validated	 according	 to	 the	 fit-for	 purpose	
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recommendations	 by	 the	 FDA.	 Evaluation	 of	 the	 in	 vitro	 and	 in	 vivo	 profiles	 thereby	
facilitated	the	identification	of	suitable	combination	candidates.	




Overall,	 the	 investigation	 enabled	 the	 identification	 of	 drug	 combinations	 that	 are	
potently	active	in	vitro.	This	synergistic	interaction	strongly	supports	the	redox	cycling	
rationale	 for	 identifying	 new	 antimalarial	 therapies	 and	 further	 suggests	 that	 such	
combinations	in	chemotherapy	may	delay	the	onset	of	resistance	to	the	new	agents.	The	









































































































































































































































persistent	 need	 for	 improved	 control	 and	 treatment	 measures,	 especially	 in	 endemic	
countries.	 Unfortunately,	 the	 effective	 control	 of	 malaria	 is	 hampered	 by	 increasing	
tolerance	 to	 first-line	 artemisinin-based	 combination	 therapies.	 Continuing	 efforts	 are	




combined	 with	 a	 redox-active	 compound	 to	 counter	 the	 progression	 of	 the	 parasite’s	
tolerance	towards	artemisinin	therapies.	This	proposal	is	based	on	evidence	that	suggests	
artemisinins	 function	 as	 intracellular	 oxidants.	 Amplification	 of	 this	 action	 by	 a	 redox	
partner	can	overwhelm	intrinsic	parasite	mechanisms	that	maintain	redox	homeostasis.	
The	effect	of	redox	 cycling	may	be	assessed	by	 the	known	redox	drug	methylene	blue	
(MB).	 The	 rapid	 oxidation	 by	 intracellular	 oxygen	 of	 the	 reduced,	 colourless	 form	













different	 species	 of	 Plasmodium	 can	 infect	 humans,	 namely	 P.	 falciparum,	 P.	 vivax,	 P.	
malariae,	P.	ovale	and	P.	knowlesi.	The	highest	prevalence	of	malaria	infections	outside	of	
Africa	arise	from	P.	vivax,	occurring	mainly	in	South-East	Asia,	the	Western	Pacific	and	
some	 parts	 of	 the	 Americas.1	 However,	 falciparum	 malaria	 has	 the	 widest	 global	
distribution.	It	is	most	prevalent	in	Africa	and	results	in	the	highest	mortality	rates.2,3		
According	 to	 the	 World	 Health	 Organisation	 (WHO)	 2019	 World	 Malaria	 Report,	 an	





the	 global	 estimated	 deaths	 from	 malaria	 per	 year	 was	 reported	 to	 have	 decreased	
considerably	from	585	000	in	2010	to	405	000	in	2018.	Children	under	the	age	of	5	are	
particularly	 susceptible	 to	 the	 disease	 and	 constituted	 272	000	 deaths	 in	 2018.	
Unfortunately,	there	are	still	many	challenges	to	overcome	in	accomplishing	the	goals	that	
the	WHO	has	 set	out	 in	 their	Global	Technical	Strategy	 for	Malaria	 for	2016–2030,	 for	
achieving	 malaria	 elimination.	 Of	 these,	 the	 goals	 to	 eliminate	 malaria	 transmission	





















vector	 once	 a	 mosquito	 takes	 a	 blood	 meal	 from	 an	 infected	 human,	 which	 initiates	












Clinical	 manifestation	 of	 malaria	 infection	 occurs	 during	 the	 blood	 stage	 and	 is	
categorized	as	either	uncomplicated	or	severe	malaria.	The	general	symptoms	of	malaria	
infection	 are	 described	 as	 nonspecific	 and	 flu-like,	 and	 may	 include	 fever,	 headache,	
fatigue,	 jaundice	and	 gastrointestinal	disturbances.10	As	 result	of	 this,	 diagnosis	of	 the	
malaria	 infection	 is	 sometimes	 overlooked,	 which	 causes	 a	 delay	 in	 treatment	 and	
escalation	of	the	severity	of	the	infection.	Fatal	complications	my	arise	in	the	case	where	
the	 diagnosis	 and	 treatment	 are	 not	 promptly	 initiated.	 This	 is	 referred	 to	 as	 severe	
malaria	in	which	P.	falciparum	can	cause	obstruction	and	eventual	rupture	of	the	small	
capillaries	of	the	brain	by	sequestered	parasites.7		Severe	malaria	is	frequently	found	in	
young	 children	 and	 presents	 more	 serious	 symptoms	 such	 as	 multiple	 convulsions,	
















travel	 to	 the	 midgut	 of	 the	 mosquito	 and	 fuse	 to	 form	 a	 zygotes	 which	 mature	 into	
ookinetes.	Ookinetes	 cross	 the	 epithelial	 cell	wall	 of	 the	mid-gut	 and	 become	 oocysts,	
containing	sporozoites.15	The	mosquito	life	cycle	is	complete	when	the	oocysts	rupture,	




Sporozoites	 contained	 in	 the	 salivary	 glands	 of	 mosquitoes	 are	 injected	 into	 the	
circulatory	system	of	a	human	host	during	a	blood	meal.	This	initiates	the	exoerythrocytic	
stage	whereby	the	uninucleate	sporozoites	invade	the	liver	parenchymal	cells	5–21	days	





Figure	 1-3:	 Thin	 blood	 smears	 of	 Plasmodium	 falciparum	 infected	 erythrocytes	
stained	with	Giemsa;	a)	small	ring	stage	trophozoites	and	b)	mature	trophozoites.	









merozoites	 which	 may	 then	 infect	 new	 RBCs	 and	 start	 the	 blood	 stage-schizogony	










WHO,	 should	 include	better	diagnostic	 tools	 for	early	detection	and	prompt	 treatment	
with	 effective	 drug	 combinations.	 The	 risk	 of	 infection	 is	 reduced	 by	 indoor	 residual	
spraying,	 long-lasting	 insecticide-treated	 mosquito	 nets	 and	 intermittent	 preventive	






has	 been	 developed.	However,	Phase	 III	 clinical	 trials	 showed	 only	modest	 protection	
against	 infections.20	 Although	 the	 need	 is	 urgent	 for	 a	 vaccine	 that	 can	 provide	 long-
lasting	 sterile	 protection,	 the	 RTS,S/AS01	 vaccine	 candidate	 may	 still	 offer	 valuable	




blood	stage	parasites	are	the	primary	target	 for	drug	development,	because	this	 is	 the	
stage	of	the	disease	responsible	for	symptoms	and	patient	death.	In	the	last	decade,	the	
generation	of	new	compounds	targeting	previously	overlooked	molecular	targets	at	the	
blood	 stage	 has	 benefitted	 from	 collaboration	 between	 academic	 institutions	 and	
industry.	 These	 efforts	 have	 delivered	 leading	 compounds	 that	 are	 currently	 being	
evaluated	 in	 clinical	 trials.	 Examples	 include	 the	 spiroindolone	 KAE609	 developed	 by	
Novartis	which	targets	the	sodium	channel	PfATP4,23,24	the	imidazolopiperazine	KAF156	




Clinical	 treatment	 of	 malaria	 infections	 depend	 on	 several	 different	 classes	 of	 drugs	




1-1).27,28	 Some	 tetracycline	 and	 erythromycin	 antibiotics,	 like	 doxycycline	 and	
azithromycin,	 are	 considered	 useful	 against	 malaria	 and	 are	 mainly	 used	 for	
chemoprophylactic	 therapy.29	Although	slow	acting,	 they	 can	be	 clinically	useful	when	
combined	 with	 artemisinin	 derivatives	 or	 quinolones	 for	 the	 follow-up	 treatment	 of	
severe	malaria.30,31	Many	of	these	compounds	have	been	used	in	combination	therapy.	For	
example,	the	arylamino	alcohol	derivative	lumefantrine	is	co-formulated	with	artemether	
as	 CoartemÒ	 and	 administered	 in	 current	 first-line	 artemisinin-based	 combination	









































































































































































The	 quinoline	 derivative	 chloroquine	 (CQ)	 was	 once	 the	 most	 widely	 used	 of	 all	
antimalarial	drugs.	However,	due	to	widespread	 resistance	to	CQ,	 treatment	shifted	 to	
other	drugs.32,33	The	4-aminoquinolines	are	highly	active	against	the	blood	stage	of	the	
malaria	parasite	lifecycle	and	their	mechanism	of	action	is	proposed	to	selectively	inhibit	



















circulation	 times	 and	 thus	 hinder	 malaria	 transmission.39,40	 Tafenoquine,	 a	 newer	 8-
aminoquinoline,	 has	 greatly	 improved	 in	 vitro	 activity	 and	 in	 vivo	 half-life	 over	
primaquine.	 Concerns	 exist	 regarding	 the	 use	 of	 high	 doses	 of	 primaquine	 and	
tafenoquine	in	populations	with	glucose-6-phosphate	dehydrogenase	(G6PD)	deficiency,	
as	 the	 high	 dosages	 of	 these	 drugs	 may	 cause	 haemolytic	 toxicity	 in	 these	 deficient	
individuals.38,41	 Further	 demonstration	 of	 haemolytic	 toxicity	 was	 found	 in	 a	 study	
completed	by	Chu	et	al.,	where	the	standard	high	dose	of	piperaquine	(0.5	mg/kg	or	1.0	
mg/kg	per	day	 for	14	or	7	days,	 respectively)42,43	was	administered	 to	 investigate	 the	
radical	cure	efficacy	of	P.	vivax	malaria	on	the	Thai-Myanmar	border.42	However,	Bancone	







nicotinamide	 adenine	 dinucleotide	 phosphate	 (NADPH)	 oxidoreductase,	 which	 is	
essential	for	its	gametocytocidal	efficacy.	This	process	allows	oxidation	of	primaquine	by	
CYP2D6	to	hydroxy-primaquine.	Subsequent	oxidation	results	in	quinone-imine	and	the	






Antifolates	 are	 made	 up	 of	 two	 classes	 of	 drugs:	 dihydropteroate	 synthase	 (DHPS)	
inhibitors	(Class	I)	and	dihydrofolate	reductase	(DHFR)	inhibitors	(Class	II).	Sulfa	drugs	
are	 inhibitors	 of	DHPS	which	 inhibit	de	 novo	 folate	 synthesis	 in	 the	 parasite,	whereas	
DHFR	 inhibitors	 affect	 activity	 of	 the	 parasite's	 bifunctional	 DHFR-thymidylate	
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synthetase	 protein.	 Drugs	 of	 these	 two	 classes	 interact	 synergistically	 and	 are	 co-
formulated.48	 Examples	 of	 co-formulations	 include	 FansidarÒ	 (sulfadoxine	 +	
pyrimethamine)	or	MalaroneÒ	 (atovaquone	+	proguanil),	among	others.	 Sulfadoxine	+	
pyrimethamine	 are	 often	 used	 in	 combination	 with	 other	 drugs.	 In	 Uganda,	 triple	
combinations	 of	 sulfadoxine	 +	 pyrimethamine	 with	 CQ	 showed	 improved	 efficacy	
outcomes.49	 Combinations	 with	 amodiaquine	 or	 mefloquine	 was	 used	 as	 low-cost	
alternative	 and	effective	 treatment	 in	African	 regions	 of	 high	 CQ	resistance.	However,	
widespread	resistant	mutations	in	parasites	from	eastern	and	southern	Africa	have	since	
led	 to	 the	 efficacy	 surveillance	 of	 populations	 receiving	 those	 combinations	 and	 the	
implementation	 of	 ACT.50	 Today,	 the	 WHO	 recommends	 that	 sulfadoxine	 +	
pyrimethamine	 be	mainly	 used	 as	 intermittent	 preventative	malaria	 treatment	 during	
pregnancy.	It	is	also	provided	for	infants	in	moderate-to-high	transmission	areas	in	Africa.	











Traditional	Chinese	medical	 literature	describes	various	applications	of	 the	 traditional	





principle	 of	 qinghao'.54	 Clinical	 trials	 were	 launched	 as	 early	 as	 1974	 and	 the	




begun	 to	 spread,	 the	 introduction	 of	 artemisinin	 was	 particularly	 timely,	 and	 by	 the	
1990’s	 it	 was	 widely	 used	 in	 Thailand,	 Burma,	 and	 Vietnam.	 Many	 derivatives	 of	







antimalarial	 activity	 of	 artemisinin	 fall	 in	 two	 categories:	 radical-dependent	 toxic	 and	
inhibitory	effects	of	artemisinin	on	vital	parasite	macromolecules,	and	interference	with	
the	parasite	Hb	degradation	and	haem	detoxification	pathways.60	Despite	 the	different	









the	 RBC,	 resulting	 from	 the	 increased	 generation	 of	 lipid	 peroxides,	 leads	 to	 an	
unfavourable	environment	for	parasite	proliferation.64	The	parasite	is	presumably	able	to	
withstand	these	severe	conditions	during	its	intra-erythrocytic	proliferation	by	utilizing	
two	 inherent,	 highly-elaborate	 redox	 (reduction/oxidation)	 systems.	 The	 thioredoxin	
 
16 
(Trx)	 and	 glutathione	 (GSH)	 redox	 systems,	 among	 other	 additional	 mechanisms,	 are	
thought	to	play	a	pivotal	role	in	active	redox	defence.65		
These	 redox	 systems	 are	 dependent	 on	 a	 constant	 supply	 of	 NADPH.	 In	P.	 falciparum	
parasites,	NADPH	is	supplied	by	G6PD	and	6-phosphogluconolactonase	for	downstream	
redox	 reactions.66–69	 As	 shown	 in	 Figure	 1-8a,	 the	 presence	 of	 NADPH	 allows	 GSH	
reductase	(GR),	Trx	reductase	(TrxR),	and	other	flavin	disulfide	reductases70	 to	reduce	
flavin	 cofactors	 such	 as	 flavin	 adenine	 dinucleotide	 (FAD)	 and	 flavin	 mononucleotide	
(FMN).70–72	The	reduced	FAD	and	FMN	are	then	able	to	provide	electrons	for	the	reduction	
of	 oxidised	GSH	 (GSSG)	 and	Trx-disulfide	 (TrxS2)	 to	GSH	 and	 reduced	Trx	 (Trx(SH)2),	
respectively.	 This	 step	 essentially	 intercepts	 ROS	 and	 thereby	 maintains	 intracellular	
redox	homeostasis.73–75		
Artemisinins	have	been	shown	to	rapidly	oxidise	FADH2,	FMNH2,	and	other	reduced	flavin	
cofactors	 (Figure	 1-9).	 As	 further	 illustrated	 in	 Figure	 1-8b,	 this	 action	 will	 prevent	
downstream	 reduction	 of	 GSSG	 and	 TrxS2,	 interrupts	 the	 parasite’s	 cycle	 of	 redox	
homeostasis,	and	leads	to	potentiation	of	ROS.	It	is	this	production	of	ROS	that	is	believed	
to	 be	 responsible	 for	 parasite	 death.	 Therefore,	 artemisinins	 can	 act	 as	 exogenous	
peroxides	enhancing	the	generation	of	ROS,	which	overwhelms	the	delicately-balanced	
parasite	 antioxidant	 defence	 system.76	 Additionally,	 supply	 of	 	 NADPH	 via	 the	 G6PD-
catalyzed	 step	has	 to	be	enhanced	 in	 the	 infected	erythrocyte.	This	however	 is	 a	 rate-










malaria.79	 ACTs	 combinations	 became	 the	 first-line	 treatment	 regimens	 for	
uncomplicated	malaria	due	to	high	resistance	in	endemic	countries.	Since	the	first	ACT	
(artesunate	 +	 mefloquine)	 was	 released	 in	 Thai-Myanmar	 in	 1994,	 there	 have	 been	
multiple	other	combination	regimens	explored	which	include	an	artemisinin.80	According	
Figure	1-9:	Artemisinin	is	irreversibly	reduced	by	reduced	conjugates	of	flavin	cofactors	
FAD,	 FMN,	 and	 other	 reduced	 flavins,	 e.g.,	 riboflavin	 (RF),	 to	 the	 inert	
deoxyartemisinin.77,78		
	
Figure	 1-8:	Management	 of	 redox	 homeostasis	within	 the	 parasite.	 a)	 The	mechanism	of	
NADPH-modulated	 active	 redox	 defence	 in	 the	 Plasmodium	 parasite,	 which	 results	 in	
intracellular	 redox	 homeostasis.	 b)	 The	 addition	 of	 artemisinin	 disrupts	 efficient	 redox	
homeostasis	 and	 results	 in	 oxidative	 stress.	 Upon	 exhaustion	 of	 artemisinin,	 the	 redox	



















approach	 has	 been	 effective,	 there	 has	 been	 increasing	 evidence	 of	 resistance	 being	
formed	against	the	partner	drug,	as	in	the	case	with	DHA	+	piperaquine	or	artesunate	+	
mefloquine	combinations.82,83	It	has	been	suggested	that	triple	ACT	(TACT)	therapies	may	
offer	 effective	 treatment	 and	 preserve	 artemisinin	 efficacy	 in	 efforts	 to	 mitigate	 the	
spread	 of	 resistance.84	 According	 to	 a	 review	 recently	 published	 by	 Rosenthal,	 this	
strategy	presents	two	main	advantages:	resistant	parasites	are	still	killed	by	artemisinins	
and	 ACT	 partner	 drugs	 have	 opposing	 resistance	 mechanisms.85	 Van	 der	 Pluijm	 and	
colleagues	demonstrated	the	efficacy	of	DHA	+	piperaquine	+	mefloquine	and	artemether	
+	lumefantrine	+	amodiaquine	TACT	in	a	multicentre	study	in	areas	which	had	established	
ACT	 resistance	 or	 a	 high	 threat	 thereof.	 The	 researchers	 concluded	 that	 these	
combinations	 are	 safe	 and	 efficacious	 in	 areas	 with	 artemisinin	 and	 partner	 drug	




Artemisinins	 are	 notably	 effective	 and	 from	 2000–2015	 had	 a	 significant	 impact	 on	
malaria	 prevalence	and	 control.19	 In	 the	 early	 2000’s,	 ACTs	 started	 to	become	 readily	
available	in	the	highest-burden	countries,	after	resistance	to	the	then	first	line	therapies	
such	as	CQ	and	sulfadoxine-pyrimethamine	became	a	major	issue.86	From	2006	onwards,	
the	ACTs	were	 deployed	 as	 first-line	 therapy.87	 However,	 there	 is	 increasing	 evidence	
which	 shows	 that	 the	Plasmodium	 parasites	are	becoming	 resistant	 to	ACTs.	Declining	
clinical	 efficacy	 of	 DHA-piperaquine	 first-line	 treatment	 was	 recently	 reported	 in	
southeast	Asia.	Furthermore,	rapid	regional	spread	of	parasite	mutations	was	observed	
for	genes	associated	with	decreased	artemisinin	efficacy.88	This	emergence	of	resistance	





Resistance	 to	 artemisinins	 is	 clinically	 defined	 as	 a	 delay	 in	 the	 time	within	which	P.	
falciparum	parasites	are	cleared	from	the	blood	of	a	malaria	patient	treated	with	an	ACT	
or	artesunate	monotherapy.89	The	first	evidence	of	ACT	resistance	was	reported	in	2009	
in	Pailin,	western	Cambodia	as	a	100-fold	 reduction	 in	parasite	 clearance	 rate.87	 Since	
then,	artemisinin	resistance	has	been	defined	as	a	parasite	clearance	half-life	≥5	hours	
following	 treatment	 with	 artesunate	 monotherapy	 or	 an	 ACT.90	 In	 2012,	 Phyo	 et	 al.	
examined	the	spread	of	resistance	from	Cambodia	to	the	Thailand-Myanmar	border.	The	
researchers	found	that	a	geometric	mean	of	parasite	clearance	times	increased	from	2.6	
hours	 in	2001	 to	3.7	hours	 in	2010,	 in	 comparison	 to	a	mean	of	5.5	hours	 in	western	
Cambodia	measured	between	2007	and	2010.91	Data	from	a	study	completed	in	2013	by	
Ashley	 et	 al.	 shows	 that	 artemisinin	 resistance	was	 already	 then	 firmly	established	 in	
parts	 of	 Myanmar,	 Cambodia,	 Thailand,	 and	 Vietnam	 which	 manifested	 as	 increased	
parasite-clearance	 times	 as	 a	 result	 of	 reduced	 susceptibility	 of	 ring-stage	 parasites.	










ACT	 resistance	 has	 been	 detected	 in	 five	 countries	 of	 the	 Greater	 Mekong	 subregion	
(GMS),	which	 includes	Cambodia,	Myanmar,	Lao,	Vietnam,	and	Thailand.54,79	Currently,	
five	ACTs	are	recommended	by	the	WHO	in	the	Greater	Mekong	subregion:	artemether	+	
lumefantrine,	 artesunate	 +	 amodiaquine,	 artesunate	 +	 mefloquine,	 artesunate	 +	
sulfadoxine-pyrimethamine,	 and	 DHA-piperaquine.	 However,	 first	 line	 treatment	with	
DHA-piperaquine	 in	 Thailand	and	Cambodia	has	 since	been	 replaced	with	 artesunate-






depends	 on	multiple	 factors,	 which	 include	 the	mechanism	 of	 drug	 action,	 efficacy	 of	
parasite	 elimination,	 PK	 profile	 of	 the	 drug,	 and	 parasite	 transmission	 dynamics.32	
Researchers	 discovered	 that	 a	 single-point	mutation	 on	 the	 parasite	 	 chromosome	13	
containing	a	gene	which	codes	for	the	Kelch13	protein	is	associated	with	longer	parasite	
clearance	 times.92,93	 Furthermore,	 research	by	Ashley	 et	 al.	 in	 2013	demonstrated	 the	
correlation	 of	 single-nucleotide	 polymorphisms	 in	 the	Kelch13	propeller	 domain	with	





























endemicity.97	 Combination	 therapy	 offers	 an	 array	 of	 advantages	 over	 monotherapy.	
Firstly,	drugs	used	in	combination	should	be	more	effective	than	those	used	alone.	This	
highlights	the	principle	of	synergy,	which	is	a	‘favourable’	drug	interaction	and	can	greatly	
assist	 the	 potency	 of	 some	 drugs.	 Dorsey	 et	 al.	 demonstrate	 this	 principle	 with	 the	
improved	 efficacy	 of	 sulfadoxine	 +	 pyrimethamine	 combinations	 in	 African	 patients,	




















the	 action	 of	 the	artemisinin	 should	elicit	 potent	 activity	against	 the	malaria	parasite.	
Importantly,	one	should	also	be	mindful	of	the	partner	compound’s	half-life	to	avoid	PK	
mismatch	 in	 these	 combinations.	 Half-lives	 should	 be	 long	 enough	 to	 eliminate	 any	
remaining	parasites	that	escaped	the	initial	rapid	clearance	by	the	artemisinin,	but	not	
extensively	 long	 as	 to	 leave	 the	 remaining	 partner	 compound	 susceptible	 to	 develop	
resistance.101	 The	 rational	 for	 this	 research	 project	 is	 to	 identify	 drugs	which	 amplify	
oxidative	 stress	 through	 their	 action	 against	 flavoenzyme	 cofactors	 which	 modulate	
intracellular	redox	homeostasis	utilizing	NADPH.70	These	redox	drugs	are	reduced	by	the	
same	flavoenzymes	responsible	for	maintaining	homeostasis.	The	reduced	drug	in	turn	is	




Oxidative	 stress	 is	 defined	 as	 the	 imbalance	 between	 antioxidants	 and	 pro-oxidants,	
whereby	 the	 latter	 are	 increased	 and	 oxygen-based	 damage	 to	 the	 host’s	 cellular	
environment	 ensues	 and	 antioxidant	 activity	 is	 diminished.102,103	 ROS	 and	 reactive	
nitrogen	species	(RNS)	are	the	most	prominent	agents	involved	in	oxidative	stress	and	
are	 generally	 cytotoxic.104	 Conversely,	 ROS	 and	 RNS	 also	 fulfil	 various	 protective	
biological	roles	in	host	defence	mechanisms,	such	as	cellular	signalling	and	apoptosis.97	




Oxidative	 stress	has	detrimental	biochemical	 consequences	and	contributes	 to	 several	
human	 pathologies,	 such	 as	 cancer,	 vascular	 disease,	 neurodegeneration,	 and	









occurs	 via	 two	 distinct	 mechanisms;	 either	 by	 the	 activation	 of	 the	 host’s	 immune	
response,107	or	via	the	degradation	of	haem	within	the	DV	of	the	intracellular	parasite.108		
The	 first	 mechanism	 involves	 production	 of	 inflammatory	 cytokines	 tumour	 necrosis	
factor	alpha	and	interferon	gamma	in	response	to	infection	of	RBCs,	as	these	increase	ROS	
production	and	phagocytosis.107		
The	 second	 mechanism,	 as	 briefly	 described	 in	 Section	 1.2.3.1.,	 occurs	 following	 the	
metabolic	breakdown	of	Hb	 to	 haem	and	globin.	 The	 rapidly	growing	 and	multiplying	
parasite	 is	exposed	to	oxidative	stress	during	the	blood	stage	of	 the	 lifecycle,	resulting	
from	ROS	 formed	as	a	 by-product	of	Hb	metabolism.109	 Hb	 is	 the	main	 food	 source	 of	
parasites.	 As	 mentioned	 previously,	 Hb	 is	 metabolised	 in	 a	 stepwise	 manner	 in	 the	
parasite’s	acidic	DV.	The	haem	 [Fe(II)PPIX]	 is	separated	 from	globin	by	proteases.	The	


























Figure	 1-11:	 Electron	 microscopy	 image	 of	 a	 P.	 falciparum	 infected	 erythrocyte	





in	 three	 system.	 The	 first	 group	 includes	 superoxide	 dismutase,	 catalase	 and	 GSH	
peroxidase,	 which	 are	 responsible	 for	 the	 dismutation	 of	 superoxide	 and	 limits	 the	
formation	of	H2O2.	The	second	category	 is	 the	Trx-dependent	system	comprised	of	Trx	
and	peroxiredoxins,	which	 reduce	 protein	disulfides	and	 are	maintained	by	TrxR.	 The	
third	 group	 includes	 GR	 which	 converts	 H2O2	 to	 water,	 while	 reduced	 GSH	 scavenge	
.OH.104,115	











NADPH	 through	 the	 pentose	 phosphate	 pathway,	 G6PD	 or	 6-phosphogluconate	
dehydrogenase.109,118	P.	 falciparum	 also	 possesses	 a	 functional	 Trx	 system	 comprising	
TrxR119,120	and	Trx-dependent	peroxidases121	as	well	as	a	1-cys-peroxiredoxin.122	The	Trx	
redox	cycle	is	proposed	to	be	essential	for	the	biological	function	and	survival	of	blood	







CQ	 is	 an	 excellent	 example	 of	 a	 clinically	 used	 drug	 that	 exerts	 its	 effect,	 in	 part,	 by	






drugs	that,	 in	part,	elicit	 their	efficacy	by	creating	a	disruption	 in	the	redox	regulatory	
pathways	 in	P.	 falciparum.	 It	has	been	 shown	 that	P.	 falciparum	may	 be	 vulnerable	 to	
redox	 cycling	 drugs	 that	 are	 able	 to	 disrupt	 redox	homeostasis	maintained	within	 the	
parasite.	These	drugs	are	then	able	to	increase	intracellular	ROS	levels	and	overwhelm	
the	parasite	homeostasis	mechanisms.125,126	
Redox	 cycling	 drug	 combinations	 rely	 on	 the	 oxidant	 and	 redox-active	 drug	 to	 work	
together	 to	establish	and	maintain	 the	 intracellular	ROS	production.	The	parent	redox	
molecule	 is	 reduced	 in	 the	 presence	 of	 reduced	 flavin	 cofactors,	 such	 as	 FADH2	 and	
FMNH2.	 The	 oxidation	 of	 the	 reduced	 conjugate	 by	 intracellular	 oxygen	 restores	 the	
Figure	 1-13:	 Thioredoxin	 and	 glutathione	 redox	 systems.	 A	 proposed	 link	 of	 the	





regenerated	 parent	 molecule	 is	 available	 again	 for	 reduction	 by	 the	 reduced	 flavin	
cofactors,	resulting	in	redox	cycling	and	build-up	of	ROS.	Additionally,	the	oxidant	drug	
component	 interrupts	 the	 electron	 transfer	 by	 the	 abrupt	 oxidation	 of	 reduced	 flavin	
cofactors.77		
An	example	of	the	action	of	the	oxidant	drug,	as	discussed	previously	in	Section	1.2.3.2,	is	
the	 reduction	 of	 artemisinin	 to	 the	 inert	 deoxyartemisinin,	 producing	 overwhelming	
build-up	of	ROS	in	the	parasite	(Figure	1-8)	resulting	in	parasite	death.	However,	redox	





increasing	 the	production	of	ROS.127	Blank	et	al.	proposed	 that	 the	mechanism	 for	 the	
biological	 effects	 of	 MB	 are	 likely	 due	 to	 its	 redox	 cycling	 abilities	 together	 with	











While	 redox-active	 compounds	 like	 MB129	 or	 1,4-naphthoquinones66	 have	 shown	 to	
increase	 oxidative	 stress	within	 the	 erythrocyte,	 Belorgey	 et	 al.	 suggested	 that	 higher	
levels	of	oxidative	stress	may	serve	as	protection	against	malaria	infection	by	increasing	
ring-stage	 phagocytosis	 rather	 than	 by	 direct	 inhibition	 of	 parasite	 growth.125	
Furthermore,	the	safety	and	efficacy	of	MB	was	assessed	in	a	clinical	study	in	Burkina-
Faso	 in	 G6PD-deficient	 patients	 with	 uncomplicated	 falciparum	 malaria.130,131	
Combinations	 of	 MB	 with	 artesunate	 or	 amodiaquine	 administered	 to	 children	 with	
uncomplicated	malaria	 demonstrated	 enhanced	 overall	 efficacy	 by	 the	 addition	 of	 the	














(non-human	models)	 and	 clinical	 research	 (human	 studies).	 Pre-clinical	 research	 can	
further	be	subdivided	into	various	areas	of	speciality,	in	which	each	area	filters	the	best	
potential	candidates	that	could	qualify	for	clinical	studies.133	Figure	1-16	depicts	the	flow	
of	 compounds	 from	 early	 identification,	 to	 lead	evaluation,	 rational	design,	 and	 finally	
candidate	selection.	Drug	development	of	novel	antimalarial	compounds	can	be	achieved	
by	 many	 different	 approaches.	 Efforts	 have	 been	 made	 to	 improve	 drugs	 that	 are	
currently	used	in	antimalarial	therapy,	for	example,	by	optimising	the	parent	scaffold	for	
which	 parasites	 have	 acquired	 resistance.	 However,	 the	 discovery	 of	 novel	 classes	 of	




Drug	 discovery	 starts	 from	 the	 simplest	 (biochemical	 assays)	 and	 continues	 to	
increasingly	complex	models.	The	pipeline	produces	data	from	a	chain	of	experiments	and	



















with	 animal	 testing.136,137	 It	 is	 advised	 that	 data	 from	 in	 silico	 and	 in	 vitro	 studies	 be	




Drug	 discovery	 and	 development	 typically	 involves	 screening	 a	 library	 of	 compounds	
with	 several	modifications	or	variations	 to	 a	 scaffold,	 to	 identify	new	compounds	 that	
possess	useful	activity.	For	this	approach	to	be	feasible	and	efficient,	HTS	methodologies	
should	be	 in	place	 in	order	to	ensure	fast	 turn-around	time	of	data	between	medicinal	
chemists	and	biologists.	The	Medicines	for	Malaria	Venture	(MMV)	have	created	an	open	
source	drug	discovery	concept	that	allows	the	research	community	access	to	hundreds	of	
unique	 compounds	 for	 screening	 of	 antiplasmodial	 activity.	 This	 “Malaria	 Box”	 of	
potential	 chemical	 starting	 points	 can	 be	 obtained	 from	 the	MMV	 and	 can	 be	 used	 to	
investigate	potential	antimalarials	and	identify	how	these	compounds	function.134,141	
Many	 different	 techniques	 and	 technologies	 have	 evolved	 to	 evaluate	 potential	
antimalarial	 compounds.	 In	 vitro	screening	 of	 potential	 antimalarial	 compounds	 is	 the	
fundamental	method	of	identifying	compounds	with	antiplasmodial	activity	and	is	made	
possible	 through	 the	 ability	 to	 culture	 P.	 falciparum	 parasites	 in	 vitro	 in	 human	
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erythrocytes.	 This	 involves	 the	 proliferation	 of	 parasites	 in	 culture	 medium	 (CM)	
containing	human	erythrocytes,	serum,	and	controlled	atmospheric	conditions,	typically	
at	 37°C	 under	 reduced	 oxygen	 concentration.142	 A	 variety	 of	well-characterised	 drug-
sensitive	and	drug-resistant	 clinical	parasite	 isolate	 strains	have	been	culture-adapted	












the	principle	 that	multiplying	parasites	 require	exogenous	purines	 to	 incorporate	 into	
their	 DNA.	 Radiolabelled	 hypoxanthine	 is	 a	 DNA	 precursor	 that	 is	 incorporated	 into	
parasite	DNA	and	is	therefore	a	direct	measure	of	parasitaemia,	making	it	a	very	accurate	
method	 of	 determination	 of	 parasite	 viability.146	 Parasites	 are	 incubated	with	 the	 test	
compounds	in	CM.	3H-hypoxanthine	is	added	to	the	wells	and	incubated	for	an	additional	
incubation	period.	The	cells	are	harvested,	and	the	radioactive	counts	are	measured	using	
a	 scintillation	 counter.	 The	 50%	 maximal	 inhibitory	 concentration	 (IC50)	 values	 are	
determined	by	linear	regression	analyses	of	the	resulting	dose–response	curves.147		
The	 hypoxanthine	 assay	 is	 still	 widely	 used;	 however,	 it	 is	 a	 radioactive	 product	 and	
requires	costly	consumables,	expensive	instrumentation	and	has	several	steps	to	follow	











A	 low-cost	 alternative	 for	 determining	 the	 antiplasmodial	 activity	 is	 to	 determine	 the	
parasitaemia	of	treated	and	control	parasites	by	counting	GIEMSA-stained	parasites	by	
light	 microscopy.	 However,	 this	 method	 is	 labour-intensive	 and	 is	 also	 subject	 to	
individual	variability.	Even	when	microscopists	are	highly	trained,	variability	in	counting	
and	assessing	developmental	stages	of	parasites	may	occur.148		
One	 assay	 that	 seems	 to	 solve	 the	 issue	 of	 time	 and	 cost	 is	 the	 SYBR	 Green	 (SG)	
fluorescence-based	assay	developed	by	Smilkstein	and	co-workers	in	2004.150	The	assay	
is	 reported	 to	 be	 as	 sensitive	 as	 the	 hypoxanthine	 assay	 and	 more	 suited	 for	 HTS	
environments	due	to	fast	results	and	inexpensive	preparation.147	Following	incubation	of	










strain.152	 Rodent	models	 have	 been	 used	 successfully	 for	 the	 identification	 of	 several	
antimalarials,	for	example,	mefloquine	and	artemisinin	derivatives.	The	investigation	of	
efficacy	in	animal	models	have	proven	to	be	a	fundamental	phase	in	the	drug	discovery	
and	 development	 pathway,	 as	 they	 provide	 useful	 information	 on	 efficacy,	 PK	
relationships	 and	 host-parasite	 interactions.95	 The	 drawback	 of	 non-primate	 animal	









The	 importance	 of	 investigating	 the	 ADME	 properties	 and	 toxicity	 and	 the	 role	 these	
properties	play	in	the	success	of	new	drug	candidates,	were	highlighted	in	a	review	by	Li	
published	 in	 2001.	 These	 properties	 play	 an	 essential	 role	 in	 the	 bioavailability,	
metabolism	and	efficacy	of	successful	drug	candidates.154		Furthermore,	Kola	and	Landis	




Time	 constrained	 methodologies	 for	 rapid	 data	 turnaround	 of	 a	 large	 number	 of	
compounds,	however,	are	a	major	challenge	with	regards	to	early	screening.156	The	fact	
that	in	vitro	assays	are	designed	to	be	simple	and	offer	HTS,	comes	as	both	an	advantage	





reason,	Eddershaw	et	al.	advises	that	 in	 vitro	screens	 should	be	used	as	a	 tool	 to	rank	
compounds	for	further	study,	rather	than	for	absolute	rejection	of	potential	candidates	
based	 on	 a	 single	 parameter.158	 The	 goal	 of	 ADME	 characterization	 is,	 therefore,	 to	
preliminarily	predict	in	vivo	behaviour	of	compounds	through	a	variety	of	experimental	




The	 oral	 delivery	 of	 drugs	 is	 the	 favoured	 route	 of	 administration	 due	 to	 ease	 of	
administration.	This	creates	a	criterion	for	screening	of	new	compounds,	as	absorption	
should	 be	 effective	 in	 order	 to	 achieve	 in	 vivo	 efficacy.159	 Passive	 diffusion	 across	 the	
intestinal	 epithelium	 driven	 by	 a	 concentration	 gradient	 is	 considered	 the	 major	
mechanism	of	absorption.	Physicochemical	 factors	of	drugs	that	have	an	impact	on	the	
extent	 of	 absorption	 include	 permeability	 and	 lipophilicity,	 enzymatic	 stability,	
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dissolution	 rate,	 acid	 dissociation	 constant	 (pKa),	 molecular	 size,	 and	 affinity	 for	
transporters.160	The	gastrointestinal	tract	(GIT)	is	a	complex	environment	and	therefore	
many	 biological	 factors	 can	 influence	 absorption	 such	 as	 the	 stomach	 emptying	 rate,	
intestinal	transit	time,	pre-systemic	metabolism	by	enzymes	of	the	GIT,	and	the	first-pass	
effect	 of	 the	 liver.161	 The	 permeability	 of	 a	 drug	 cannot	 be	 accurately	 estimated	 from	
physicochemical	factors,	such	as	pKa,	lipophilicity	and	solubility,	alone.		One	of	the	main	
reasons	for	this	is	because	multiple	drug-transport	pathways	exists.	An	in	vitro	model	is	
required	 for	 a	more	 accurate	 representation	 of	 the	 intestinal	mucosa.	 The	 Caco-2	 cell	
based-assay	is	currently	the	most	widely	accepted	model	for	 intestinal	permeability.154	
Caco-2	cells	are	cultured	in	24-well	plates	and	incubated	with	test	compound	to	measure	








four	 compartments	 namely:	 intracellular	 fluid	 (40%),	 plasma	 (5%),	 interstitial	 fluid	
(15%)	 and	 transcellular	 fluid	 (1%).	 Drugs	 move	 across	 epithelial	 barriers	 out	 of	 the	
plasma	 towards	 other	 fluid	 compartments	 or	 back	 into	 the	 plasma	 to	 establish	
equilibrium.	Drug	molecules	exist	in	different	compartments	either	bound	to	tissues	or	as	
unbound,	free	molecules,	as	well	as	in	equilibrium	between	ionized	and	unionized	forms.	
Therefore,	 the	 distribution	 of	 a	 drug	 between	 compartments	 are	 influenced	 by	 its	
physicochemical-	and	biochemical	properties,	 such	as	 the	pH	partition,	 the	 lipid-water	
partition,	 cell	 membrane	 permeability	 and	 the	 extent	 of	 protein	 binding	 within	 the	
compartments.164	







Exploring	 the	 plasma	 protein	 binding	 of	 a	 compound	 not	 only	 enhances	 our	










the	 liver	 via	 the	hepatic	portal	 vein,	where	 it	 is	metabolised	by	 liver	enzymes.	Highly	
lipophilic	molecules	are	transformed	and	metabolised	for	eventual	excretion.	The	liver	is	




Drug	 metabolism	 can	 be	 divided	 into	 two	 categories.	 Phase	 I	 metabolism	 consists	 of	
enzymes	 from	 the	 cytochrome	 (CYP)	 P450	 family.	 The	 CYP3A4	 human	 isoform	 is	
responsible	for	almost	50%	of	xenobiotic	metabolism.	Phase	II	enzymes	are	responsible	
for	 conjugation	 of	 the	 drug	 or	 metabolite	 and	 include	 uridine	 diphosphate-












The	 body	 uses	 several	 pathways	 of	 elimination,	 which	 mainly	 involve	 the	 kidneys.170	





absorbed	 in	the	small	 intestine	and	distributed	 in	the	body,	depending	on	 its	chemical	
properties.	This	is	known	as	enterohepatic	recirculation.171	Other	pathways	of	excretion	






interactions,	 metabolism,	 or	 because	 of	 species	 or	 organ-specific	 interactions.173	
Therefore,	investigation	of	drug	toxicity	is	vital	to	the	process	of	drug	discovery.		
Screening	methodologies	are	routinely	used	for	evaluation	of	toxic	mechanisms	in	early	
pre-clinical	 studies	 for	 the	 guidance	 of	 chemical-structure	 modification	 by	 medicinal	
chemists.	 These	 assays	 mostly	 use	 tumour	 cell	 lines	 which	 contain	 little	 drug-
metabolizing	capacity	and,	therefore,	reflect	the	compound’s	intrinsic	toxicity.	Metabolic	
stability	 screening	 using	 liver	 microsomes	 such	 as	 human	 hepatocytes,	 is	 preferable,	















monkeys.175	 Animal	models	 are	 utilized	 in	 PK	 investigations	which	 can	 determine	 the	
concentration-time	 profiles,	 tolerable	 dose,	 drug	 interaction	 and	 toxicity	 of	 novel	
compounds	 during	 the	 candidate	 screening	 process.176,177	 PK	 studies	 involve	 taking	
multiple	blood	samples	over	a	period	of	time	after	a	dose	of	the	drug	was	administered	to	
healthy	 animals.178	 Compounds	 can	 be	 dosed	 singly	 or	 as	 part	 of	 a	 cassette	 dosing	
strategy,	which	involves	the	dosing	of	multiple	compounds	to	a	single	animal.	The	latter	
method	has	 the	advantage	of	HTS	of	 candidate	 compounds,	however	 this	method	also	
increases	 the	 likelihood	 of	 potential	 drug	 interactions.179	 The	 biological	 samples	 are	
quantitatively	 analysed	 and	 the	 resulting	 PK	 parameters	 allow	 interpretation	 of	 the	
ADME	properties	of	the	drug.178	While	ADME	screening	is	a	relatively	accessible	in	vitro	














The	 aim	 of	 this	 project	 is	 to	 identify	 compounds	 that	 are	 active	 and	 selective	 against	
sensitive	and	resistant	strains	of	P.	falciparum.	Favourable	compounds	will	have	their	PK	
evaluated	 in	 order	 to	 identify	 compounds	 with	 desirable	 properties.	 Lastly,	 further	





P.	 falciparum	 strains	 and	which	 could	 potentiate	 generation	 of	 ROS	 and	 redox	
cycling.		
o Develop	and	partially	validate	 quantitative	LC-MS/MS	methods	 for	 the	 selected	
compounds.	
o Determine	the	ADME	drug-like	properties	of	the	compounds	using	the	following	in	
vitro	 assays:	 kinetic	 solubility,	 lipophilicity,	 membrane	 permeability,	 plasma	

















treatment	 of	malaria	 caused	 by	P.	 falciparum,	 the	most	 severe	 of	 the	 five	Plasmodium	








tolerated	 and	 high-quality	 drugs	 for	 use	 in	 combination	 therapies	 malaria	 have	
increased.185,186		





been	 identified	 within	 the	 various	 stages	 of	 the	 parasite	 life	 cycle	 and	 drugs	 can	 be	
designed	to	target	those	specific	sites.	Asexual	blood	stages	are	the	logical	target	site,	as	
these	 proliferating	 parasites	 are	 responsible	 for	 the	 clinical	 manifestations	 of	 the	
disease.188	 Furthermore,	 the	 importance	 of	 activity	 against	 sexual	 blood	 stage	
gametocytes	 that	 are	 responsible	 for	 transmission	 of	 the	 malaria	 parasites	 from	 the	
human	to	mosquito	is	now	especially	emphasized.	Any	drug	which	can	block	transmission	
of	resistant	parasite	phenotypes	for	example	will	greatly	assist	in	the	aim	of	quenching	
the	 spread	 of	 resistant	 malaria,	 and	 eventually	 assist	 in	 the	 final	 task	 of	 eradicating	
malaria.	







HTS	against	drug-sensitive	and	 drug-resistant	malaria	 strains,	 are	 deemed	 sufficiently	
active	and	are	progressed	to	the	next	phase.26,185		
	






parasite	 may	 not	 be	 known,	 it	 is	 important	 that	 toxicity	 towards	mammalian	 cells	 is	
established,	in	order	to	ensure	that	these	have	acceptable	therapeutic	indices.		
The	strategy	applied	 in	 the	collaborative	research	project	 is	 to	protect	 the	artemisinin	
component	by	including	new	partner	pro-oxidant	compounds	which,	via	redox	cycling,	
maintains	the	level	of	oxidative	stress	induced	in	an	incipient	sense	by	the	artemisinins.68	
The	 inclusion	 of	 a	 third	 partner	 for	 development	 of	 a	 potential	 TACT	 was	 also	
investigated,	 which	 involved	 derivatives	 of	 decoquinate	 (DQ),	 as	 their	 antiplasmodial	
activity	is	well	established.190	Through	the	addition	of	a	long	acting	third	partner	in	the	
combination,	 like	DQ,	 	any	parasites	remaining	 in	circulation	should	be	eliminated	and	
result	in	reducing	the	risk	of	recrudescence.			
The	 compounds	 investigated	 in	 this	project	were	 selected	 from	 five	different	 series	of	
derivatives	prepared	 in	the	Centre	of	Excellence	 for	Pharmaceutical	Sciences	at	North-




against	 CQ-sensitive	 (CQS)	 and	 CQ-resistant	 (CQR)	 strains	 of	 P.	 falciparum,	 and	
cytotoxicity	 against	 mammalian	 cells.	 The	 compounds	 are	 representative	 of	 several	
different	parent	compounds	from	which	they	are	derived,	namely	phenothiazines	(AD01)	
based	 on	 MB,	 phenoxazines	 (PhX6),	 artemisinins	 (WHN012),	 thiosemicarbazones	
(DpNEt)	and	quinolones	(RMB005)	and	quinolines	(RMB059	and	RMB060)	derived	from	














PhX6	 &	 DpNEt:	 Prof	 Chris	 Parkinson,	 School	 of	 Biomedical	 Sciences,	 Charles	 Sturt	
University,	Orange,	NSW,	Australia.		
RMB005,	 -059	and	-060:	Dr.	Richard	Beteck,	Centre	of	Excellence	 for	Pharmaceutical	







Parasite	 culturing	 methods	 and	 parasite	 survival	 assay	 methods	 are	 described	 in	
Appendix	A.		
All	 activity	 and	 cytotoxicity	 screening	 were	 completed	 by	 the	 Division	 of	 Clinical	
Pharmacology	at	the	University	of	Cape	Town,	except	for	RMB005,	RMB059	and	RMB060	
which	were	previously	completed	by	Beteck	et	al.,192,193	as	referenced	in	Table	2-3.	The	



























which	 the	 parasites	 were	 expected	 to	 be	 in	 a	 trophozoite-dominant	 growth	 phase.	






NBT	 is	 reduced	 to	 a	 purple	 formazan	 salt	 by	 APADH	 which	 was	 measured	











wells.	 This	 could	 be	 due	 to	 many	 experimental	 factors,	 including	 underestimation	 of	




reached	when	80%	of	 the	 culture	 flask	 surface	 is	 covered	with	 cells.	At	 this	point	 the	
culture	is	ready	for	subculturing	in	fresh	medium	or	for	seeding	into	plates	for	assays.194	
Confluency	 of	 the	 Chinese	 Hamster	 Ovarian	 (CHO)	 cells	 was	 observed	 under	 a	 light	
microscope	(40	x	objective).	Upon	confirmation,	cells	were	detached	using	trypsin	and	









hours	 at	 37°C.	 A	 solution	 of	 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl	 tetrazolium	
bromide	(MTT)	was	added	to	each	well.	Plates	were	left	to	develop	in	the	dark,	as	the	MTT	
is	light	sensitive.	After	MTT	is	reduced	to	its	formazan	salt	by	active	mitochondria	in	viable	









The	ability	of	 the	given	compound	 to	selectively	kill	P.	 falciparum,	was	determined	by	
calculation	of	 the	 selectivity	 index	 (SI).196	The	SI	 is	 the	 ratio	 of	 the	 cytotoxicity	 to	 the	
antiplasmodial	 activity;	 this	 indicates	 whether	 a	 compound	 is	 selectively	 toxic	 to	 the	
parasites,	and	does	not	induce	non-specific	killing	of	healthy	tissues	(Equation	2-1).	 	A	






parasites	 (Equation	 2-2).198	 This	 ratio	 indicates	 the	 susceptibility	 of	 a	 compound	 to	
develop	cross-resistance	with	 other	drug	 resistant	 strains.199	 	 The	RI	 can	 vary	 greatly	
between	parasite	strains	and	a	lower	RI	does	not	necessarily	indicate	lower	resistance,	as	










activity.	 The	 IC50	 values	 of	 the	 compounds	 mentioned	 above	 were	 assessed	 against	
asexual	blood	stages	of	the	CQS	NF54	and	CQR	Dd2	or	K1	strains	of	P.	falciparum.	From	a	
total	 of	 138	 compounds,	 seven	 were	 determined	 as	 suitable	 candidates	 for	 further	
investigation	based	on	their	high	antiplasmodial	activity	(Table	2-2).	These	compounds	
include	the	amino-artemisinin	WHN012,	the	phenothiazine	AD01,	the	phenoxazine	PhX6,	
the	 thiosemicarbazone	 DpNEt,	 and	 derivatives	 derived	 from	 decoquinate,	 namely	 the	
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AD01	 Phenothiazine	 340.5	 C20H26N3S	 	

































WHN012	 1.2	±	0.04	 9.2	±	1.9	 	 >204	±	ND	 7.6	 >1000	
>1000	
AD01	 23.1	±	2.5	 11.9	±	2.8	 	 74	±	9.4	 0.5	 >1000	
>1000	
PhX6	 41.8	±	0.04	 16.2	±	2.4	 	 192	±	4.6	 0.4	 >1000	
>1000	
DpNEt	 40.7	±	1.4	 28.6	±	4.0	 	 11	±	4.2	 0.7	 270	
384	
RMB005	 40.4	±	1.3
h	 	 64.8	±	7.2	(K1)h	 >	21	±	ND	 1.9	 528	 326	
RMB060	 1.5	±	0.5
i	 	 1.4	±	0.6	(K1)i	 >	88	±	ND	 0.9	 >1000	 >1000	
RMB059	 6.9	±	3.9
i	 	 14.4	±	6.3	(K1)i	 >	188	±	ND	 2.1	 >1000	 >1000	
CQe	 9.9	±	0.4	 142	±	16.8	 	 nd	 14.3	 nd	
nd	
ASe	 6.9	±	1.4	 18.1	±	7.1	 	 >354	±	NDf	 2.6	 >1000	
>1000	





52.6	±	4.5f	 1.1	 >1000	 >1000	
DQ	 26.6	±	1.4h	 	 64.9	±	8.8	(K1)h	 >100	±	NDj	 2.4	 >1000	
>1000	
















HIV	 therapy,202	 immunosuppression,203	 anticancer204	 and	 antitubercular	 activity.205	 In	
effort	to	develop	more	stable	and	economic	preparations	from	artemisinins,	as	discussed	
in	the	literature	review,	a	series	of	DHA-piperazines	were	prepared	by	Haynes	et	al.	with	
demonstrated	 efficacy	 and	 economic	 preparation.206	 Further	 conversion	 of	 this	 series	










be	 investigated	 in	 other	 multidrug-resistant	 strains,	 specifically	 those	 resistant	 to	
artemisinins.	 WHN012	 presented	 an	 IC50	 of	 >204	 µM	 and	 therefore	 had	 selective	
















investigated	 and	 discussed	 by	 Ng	 et	 al.,	 2007.210	 Further	 investigation	 of	 various	
derivatives	 derived	 from	 the	 C-10	 amino	 derivative	 DHA-piperazine	 (Figure	 2-1)207	
revealed	remarkable	early	and	 late	stage	gametocytocidal	activity.	WHN012	presented	
nanomolar	activities	against	early	stage	(IC50	36.0	±	10.2),	as	well	as	late	stage	(IC50	17.0	












MB	 exhibits	 its	 antiplasmodial	 activity	 have	 been	 postulated.125,127,128,211	 One	 such	
mechanism	is	 the	ability	of	MB	to	undergo	redox	cycling,212	as	described	 in	Chapter	1.	
Thus,	AD01	is	very	likely	to	undergo	redox	cycling.	




















to	 two	 benzene	 rings	 and	 found	 to	 be	 naturally	 present	 in	 insect	 pigments,	 mold	
metabolites	and	actinomycins.213	The	first	simple	angular	benzo[alpha]phenoxazine	was	
first	 reported	 by	 Goldstein	 and	 Semelicht	 in	 1919.214	 Phenoxazine	 derivatives	 have	
reportedly	diverse	biological	activities	including	antimycobacterial	activity,215	antitumor	













PhX6.	 The	 differences	 between	 PhX6	 and	 the	 benzo[α]phenoxazine	 nucleus	 are	
highlighted	in	blue.	
	








this	 benzo[α]phenoxazine	 derivative	 in	a	P.	berghei	mouse	model	 cured	 infected	mice	







Thiosemicarbazone	 derivatives	 such	 as	 DpNEt	 (Figure	 2-5),	 have	 been	 examined	 as	
anticancer	 molecules.222,223	 This	 class	 of	 compounds	 are	 modified	 from	 the	 oxygen-
containing	 semicarbazide.224,225	 As	 these	 compounds	 are	 able	 to	 chelate	 intracellular	
metal	 ions,	 Richardson	 et	 al.	 hypothesized	 the	potential	mechanism	of	 their	biological	










NF54 IC50: 11.0 nM











in	 various	 animal	 species	 with	 an	 acceptable	 food	 safety	 profile.227	 Its	mechanism	 of	
action	 against	 malaria	 parasites	 is	 through	 the	 selective	 inhibition	 of	 the	 plasmodial	
mitochondrial	bc	(1)	complex.228	DQ	was	converted	by	Beteck	et	al.	into	the	derivatives	
RMB005,	 RMB059,	 and	 RMB060	 (Figure	 2-6).192	 DQ	 showed	 low	 nanomolar	 in	 vitro	




less	 favourable	drug	to	apply	 to	 the	drug	development	 cascade.193,231	 In	 the	review	by	
Beteck	et	al.,	 the	authors	 acknowledge	 that	DQ	 is	very	affordable	and	 satisfies	 several	
MMV	TCP	 criteria	 (TCP-1,	 4,	 and	 5)	 for	malaria	 eradication.	However,	 optimization	 is	
needed	with	regards	to	its	physiochemical	properties.231	The	aims	of	recent	studies	were	










were	 analysed	 using	 the	 SYBR	 green-I	 assay,	 a	 comparative	 study	 by	 Zhang	 et	 al.	 has	
shown	that	antiplasmodial	data	from	this	assay	and	the	pLDH	assay	are	not	statistically	
different.232	RMB005’s	antiplasmodial	values	are	comparable	to	artesunate	(RI	2.6)	and	
indicate	 lack	 of	 susceptibility	 to	 cross	 resistance.	 However,	 further	 investigation	 is	
required	against	other	multiple	drug	resistant	strains	to	determine	the	susceptibility	of	










and	 d).	 Beteck	 et	 al.	modified	 the	 parent	 compound	 by	 addition	 of	 side	 chains	 to	 the	
quinolone	 nucleus,	 in	 an	 effort	 to	 potentially	 increase	 the	 extent	 of	 exposure	 in	 vivo	
through	 improved	 absorption.232	 RMB059	 and	 RMB060	 presented	 low	 nanomolar	
activities	of	6.9	nM	and	1.5	nM	respectively	against	CQS	P.	falciparum	strain	NF54.	These	
compounds	 have	 superior	 activity	 profiles	 to	 DQ,	 and	 similar	 potency	 to	 CQ	 and	
artesunate	in	the	CQS	NF54	strain.	The	activity	of	RMB059	and	RMB060	to	CQR	K1	strain	
was	 14.4	 nM	 and	 1.4	 nM,	 respectively.	 The	 RI	 of	 RMB060	 of	 <	 1	 indicates	 no	 cross-
resistance	against	CQR	strains.	RMB059	had	an	RI	of	2.1,	which	may	be	an	indication	of	
potential	 cross	 resistance	 to	CQR	strains.	However,	 the	value	 is	 still	within	acceptable	
range	in	comparison	to	artesunate	(RI	=	2.6).	Further	studies	by	Beteck	et	al.	showed	that	
RMB059	 and	 RMB060	 presented	 20–40%	 inhibition	 of	 early	 and	 late	 stage	 NF54	























A	 small	 diversity-oriented	 library	 was	 screened	 for	 antiplasmodial	 activity.	 Seven	
structurally	 diverse,	 highly	 active	 compounds	 (IC50	 <1	 µM)	 which	 lack	 nonspecific	
inhibition	of	mammalian	cells	were	selected	from	this	screening.	The	ultimate	aim	was	to	
discover	new	partner	compounds	for	use	in	ACTs.	The	compounds	PhX6,	AD01,	DpNEt,	
WHN012,	 RMB005,	 RMB059,	 and	 RMB060	 were	 selected	 based	 on	 their	 nanomolar	
antiplasmodial	 activity	 in	 CQS	 and	CQR	 strains	 of	P.	 falciparum	and	 their	 lack	 of	non-
specific	cellular	toxicity	in	mammalian	CHO	cells.	The	RIs	of	all	compounds	were	found	to	
be	below	that	of	CQ	(0.4	–	7.6),	which	indicate	low	susceptibility	of	cross	resistance.	The	





The	 ambition	 of	 the	 MMV	 is	 to	 discover	 novel	 compounds	 that	 will	 maintain	 the	
continuous	 development	process	of	 effective	malaria	 therapies	which	will	 support	 the	
ultimate	eradication	of	malaria.	They	have	compiled	TCP	criteria	 to	aid	researchers	 in	
identification	 of	 lead	 compounds.	 All	 compounds	 selected	 comply	 with	 TCP-1,	 at	





The	 compounds	 belonging	 to	 the	 RMB	 class	 are	 novel	 derivatives	 of	 an	 existing	
antimicrobial	 drug	 DQ,	 whose	 physiochemical	 properties	 are	 expected	 to	 have	 been	
improved	by	chemical	modification.	Similarly,	AD01	is	a	more	lipophilic	analogue	of	MB	
and	 is	 expected	 to	 show	poorer	 solubility	 and	absorption.	Although	great	 emphasis	 is	
placed	on	the	potency	of	antiplasmodial	compounds,	the	need	for	suitable	physiochemical	
properties	should	also	be	stressed,	as	aqueous	solubility	and	lipophilicity	may	aid	in	the	

















The	 antiplasmodial	 activity	 and	 toxicity	 of	 seven	 compounds,	 namely	 the	 amino-
artemisinin	 WHN012,	 the	 ethyl	 analogue	 AD01	 of	 MB,	 the	 phenoxazine	 PhX6,	 the	
thiosemicarbazone	 DpNEt,	 and	 the	 decoquinate	 derivatives	 RMB005,	 RMB059,	 and	
RMB060	which	were	selected	for	this	project	have	been	discussed	in	the	previous	chapter.	
For	convenience,	the	structures	of	the	compounds	to	be	examined	here	are	given	in	Figure	




Figure	 3-1:	 Structures	 of	 compounds	 selected	 for	 evaluation	 of	 physicochemical	 and	




In	 drug	 discovery,	 screening	 of	 the	 biological	 activity	 of	 compounds	 is	 followed	 by	











which	 the	 drugs	 might	 be	 exposed	 in	 vivo,	 as	 discussed	 in	 Chapter	 1.	 In	 vitro	 assays	








to	 assay	 conditions	 in	 pre-clinical	 investigations.	 Investigation	 of	 solubilities	may	 also	
provide	insight	into	how	well	the	drug	may	be	absorbed	at	the	various	pH	values	of	the	
gastrointestinal	tract	(GIT).140,235		
The	 aqueous	 solubility,	 among	 other	 physicochemical	 properties	 of	 a	 compound,	
determines	 if	 a	molecule	 will	 be	 delivered	 to,	 and	 interact	with,	 the	 pharmacological	
target.140,236	 Consequently,	 compounds	 should	 be	 soluble	 within	 the	 physiological	 pH	
range.	 Solubility	 is	 a	 key	 parameter	 that	 enhances	 bioavailability	 (BA)	 of	 orally	






The	 affinity	 of	 a	 compound	 for	 a	 lipid	 or	 aqueous	 environment	 is	 determined	 by	 the	
lipophilicity	assay,	which	is	expressed	as	a	distribution	coefficient	(LogD)	of	a	compound	
between	 1-octanol	 and	 an	 aqueous	 buffer.140	 LogD	 is	 an	 important	 parameter	 as	 it	
significantly	impacts	ADME	properties	and	gives	valuable	insights	into	structure-activity	
and	structure-property	relationships.		
In	 conjunction	with	 solubility,	 the	 extent	 of	 lipophilicity	will	 affect	 permeation	 across	
cellular	membranes.	Absorption,	distribution,	and	BA	of	a	drug	is	greatly	influenced	by	its	
distribution	between	polar	and	non-polar	environments.237	Thus,	crossing	of	epithelial	
cells	 of	 the	 intestinal	 lumen	 and	 the	 lipid	 bilayer	 of	 RBCs	 requires	 optimal	
lipophilicity.7,238		
LogD	values	between	1–3	are	considered	ideal	for	gastrointestinal	absorption	via	passive	
permeation	 and	 have	 the	 potential	 to	 increase	 oral	 BA.	 Values	 below	 1	 indicate	 the	
compounds	may	be	too	hydrophilic	and	this	could	limit	absorption	from	the	GIT,	while	




Apparent	 permeability	 (Papp)	 is	 determined	 by	 the	 parallel	 artificial	 membrane	





of	 physiological	 barriers	 such	 as	 those	 found	 in	 the	 gastrointestinal	 wall	 during	
absorption	from	the	GIT	and	diffusion	across	lipid	membranes	of	RBCs.238	
Movement	across	 cells	 can	occur	either	by	paracellular	or	 transcellular	 transport.	The	
former	involves	movement	of	small	molecules	between	tight	junctions	of	adjacent	cells	
and	does	not	require	energy	or	specific	transporters.241	The	latter	occurs	either	by	passive	
transport,	 which	 utilizes	 a	 concentration	 gradient,	 or	 an	 active	 transport	 mechanism	
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from	 the	 percentage	 remaining.	 Drug	 metabolism	 can	 occur	 in	 the	 liver,	 GIT,	 or	 by	
enzymes	present	in	the	plasma.243	The	stability	of	a	compound	in	whole	blood	or	plasma	
is	an	important	parameter	to	consider	during	drug	development,	as	it	can	contribute	to	





and	 considered	 to	 be	 one	 of	 the	 sources	 of	 complexity	 that	 is	 integral	 to	 the	 in	 vivo	
system.244	Increased	importance	is	placed	on	PPB	in	describing	PK/PD	relationships.	The	
free-drug	theory	states	that	only	free,	unbound	drug	(fu)	in	plasma	is	available	to	interact	
with,	 and	 elicit	 an	 effect	 on,	 the	 pharmacological	 target;	 and	 should	 reflect	 the	
pharmacologically	relevant	concentration	of	unbound	drug	in	tissue.245	
Drug	exposure	at	the	target	site	is	impacted	by	highly	protein	bound	drugs	and	this	will	
also	 impact	 the	 interpretation	 of	 in	 vivo	 pharmacodynamic	 data	 required	 to	 establish	




globulin	 protein,	 alfa-1	 acid	 glycoprotein	 (AAG).247	 Acidic	 drugs,	 like	 atovaquone,	 and	
neutral	drugs	bind	to	albumin	while	basic	drugs	like	quinine,	AM,	and	primaquine	bind	to	






The	 extent	 of	 binding	 to	 microsomal	 proteins	 is	 important	 for	 prediction	 of	 in	 vivo	
clearance.	 The	 intrinsic	 clearance	 is	 the	 rate	 at	which	 the	 liver	 is	 able	 to	 irreversibly	




non-specific	 binding	 to	 the	 lipid-protein	 milieu	 of	 the	 microsomal	 membrane.249	




The	 metabolic	 stability	 of	 compounds	 is	 determined	 using	 mouse	 and	 human	 liver	





preparation,	but	 are	 fundamental	 for	understanding	hepatic	 clearance	 in	 vitro	as	 they	
contain	 all	 membrane	 bound	 proteins.251	 Although	 metabolic	 studies	 involving	
microsomes	 are	 considered	 incomplete–as	 they	 do	 not	 account	 for	 non-oxidative	
processes	and	metabolism	by	cytosolic	enzymes,	they	remain	crucial	for	the	identification	
of	metabolically-unstable	compounds.252		
The	 liver	 transforms	 xenobiotics	 into	more	polar	 compounds	 to	 be	 readily	 eliminated	
from	the	system	via	the	kidneys	or	bile.235	Clearance	from	the	liver	is	a	vital	parameter	as	
it	directly	impacts	the	BA	of	orally	administered	drugs.253	This	occurs	during	Phase	I	and	
Phase	 II	 metabolism.	 Phase	 I	metabolism	 primarily	 involves	 oxidation,	 reduction	 and	
hydrolytic	 reactions	 that	 expose	 an	 existing	 functional	 group	 in	 a	 compound	 (e.g.	
demethylation)	or	create	a	new	functional	group	(e.g.	hydroxylation).	Phase	I	metabolism	
is	 mainly	 driven	 by	 cytochrome	 P450	 isoforms–found	 in	 high	 abundance	 in	
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microsomes.254	 Phase	 II	 metabolism	 involves	 conjugation	 reactions	 of	 pre-existing	
functional	groups,	or	such	groups	generated	by	Phase	I	metabolism	on	a	drug	substrate–
to	 create	 very	 polar,	 water-soluble	 metabolites	 that	 are	 easily	 excreted.235	 However,	
acetylation	 of	 compounds	 containing	 a	 primary	 amino	 group	 results	 in	 a	 more	
hydrophobic	conjugate	in	a	reaction	that	converts	the	ionised	primary	ammonium	group	
to	 an	 uncharged	 amide.255	 By	 investigating	 compounds	 in	 both	 mouse	 and	 human	






















Analytical	 methods	 were	 developed	 on	 a	 LC-MS/MS	 system	 which	 consisted	 of	 a	
Schimadzu	 high-performance	 liquid	 chromatography	 (HPLC)	 system	 (Kyoto,	 Japan),	
coupled	to	an	AB	Sciex	3200	Q	TRAP	mass	spectrometer	(AB	Sciex,	Massachusetts,	USA).	












stock	 solution	 stability;	 matrix	 stability;	 autosampler	 stability;	 recovery	 and	 matrix	
effects;	accuracy	and	precision;	and	carryover.		
The	nature	of	this	project	did	not	justify	a	full	validation,	as	prescribed	by	the	U.S.	Food	
and	 Drug	 Administration	 (FDA)	 and	 European	Medicines	 Agency	 (EMA)	 international	













• Does	 the	 method	 deliver	 accurate	 and	 precise	 results,	 within	 the	 acceptable	
variability	range?	
• What	is	the	range	in	measurements	that	provide	reliable	data?	












Aqueous	 solubility	 of	 the	 compounds	 was	 determined	 at	 various	 pH	 levels,	 using	 a	
miniaturised	 shake-flask	method.235,236	 A	 three-point	 calibration	 curve	 of	 each	 control	




HPLC	 with	 diode	 array	 detector).	 Control	 (reserpine	 and	 hydrocortisone)	 and	 test	
compound	concentrations	were	calculated	from	the	peak	area	in	the	UV	chromatogram	
by	extrapolation	from	the	calibration	curve,	using	the	relationship	in	Equation	3-1.	
Equation	 3-1.	 Linear	 regression	 relationship	 of	 concentration	 versus	 instrument	
response.	


























solution	 was	 added	 to	 the	 apical	 (donor)	 side	 of	 a	 multiscreen	 plate	 containing	 the	
artificial	hexadecane	membrane	(Figure	3-2).	The	acceptor-buffer	solution	was	prepared	
by	adding	10	µL	DMSO	to	990	µL	acceptor	buffer	(pH	7.4)	and	250	µL	were	added	to	the	
basolateral	 (acceptor)	wells.	 The	 donor	 plate	was	 carefully	 inserted	 into	 the	 acceptor	
plate	and	incubated	at	room	temperature	for	4	hours.	Theoretical	equilibrium	samples	
were	prepared	by	adding	150	µL	of	donor	solutions	to	250	µL	acceptor	solutions	and	left	
at	 room	temperature.	After	 the	 incubation	period,	50	µL	of	samples	 from	 the	acceptor	
plate	were	 transferred	 to	a	round	bottom	96-well	plate,	 together	with	30	µL	of	donor	
buffer	for	matrix	matching.	For	the	prepared	theoretical	equilibrium	samples,	80	µL	were	
added	to	the	analysis	plate.	Lastly,	160	µL	ISTD	was	added	to	all	acceptor	and	equilibrium	









(A& +	A') 	× 	D	 × 	/
	
	
where	 VA	 =	 volume	 of	 donor	 compartment	 (0.15	 cm3),	 VD	 =	 volume	 of	 acceptor	
compartment	 (0.25	cm3),	A	=	accessible	 filter	area	 (0.24	cm2)	 and	 t	=	 incubation	 time	
(14	400	seconds).	
Equation	3-4	





Where	 [drugacceptor]	 is	 the	 analyte	 to	 internal	 standard	 peak	 area	 ratio	 of	 the	 test	
compound	 in	 the	 acceptor	 compartment	 and	 [drugequilibrium]	 is	 the	 analyte	 to	 internal	
standard	peak	area	ratio	of	the	combined	total	donor	and	acceptor	compartments.	









different	deep	well	plates	 labelled	with	different	 time-points	(t0,	 t5,	 t15,	 t30,	 t60,	and	t180	
minutes).	 The	 t0	 samples	 were	 immediately	 precipitated	 with	 ice	 cold	 acetonitrile	
containing	the	internal	standard	(ISTD)	(0.1	µM	carbamazepine)	and	stored	at	-20°C	until	
analysis.	The	remaining	plates	were	placed	in	a	water	bath	at	37°C	and	precipitated	at	the	
indicated	time.	After	samples	of	 the	 final	 timepoint	were	precipitated,	 the	supernatant	
was	transferred	to	a	round	bottom	96-well	plate	for	analysis	with	LC-MS/MS.	Peak	areas	


















































to	 1	 µM	 in	 buffered	 solution	 containing	 0.4	 mg/mL	 microsomal	 protein.	 TCS	 and	
centrifuged	samples	were	prepared	in	the	same	fashion	as	described	in	Section	3.3.4.5.	
Following	centrifugation,	the	supernatant	was	transferred	to	the	plate	containing	TCS	and	
precipitated	 with	 ice	 cold	 acetonitrile	 containing	 ISTD	 (0.1	 µM	 carbamazepine).	 The	
supernatant	was	transferred	to	round	bottom	96-well	analysis	plates	and	analysed	by	LC-







a	 5-point	metabolic	 stability	 assay	 in	human	 and	mouse	 liver	microsomes.257,260	 Stock	
solutions	 of	 control	 (midazolam,	 MMV390048	 and	 propranolol)	 and	 test	 compounds	
were	diluted	in	buffered	solution	containing	0.4	mg/mL	microsomes,	in	deep	well	96-well	
plates.	 Deep	well	 plates	were	 labelled	with	 time	 points	 t0,	 t5,	 t15,	 t30,	 and	 t60	 minutes.	
Aliquots	 were	 transferred	 to	 each	 of	 the	 plates	 in	 duplicate.	 The	 t0	 samples	 were	
immediately	 precipitated	 with	 ice	 cold	 acetonitrile	 containing	 the	 ISTD	 (0.1	 µM	
carbamazepine)	and	stored	at	-20°C	until	analysis.	NADPH	was	added	to	the	remaining	
plates	to	initiate	the	metabolic	reaction	and	plates	were	placed	in	a	water	bath	at	37°C	



















































Data	 from	validation	 and	ADME	 experiments	were	 analysed	 in	 Excel	 (Microsoft	Office	
Excel,	2013)	to	obtain	mean	±	 standard	error	of	 the	mean	and	%CV,	where	applicable.	






















WHN012	 10	 24	 27	
AD01	 >150	 >150	 >150	
PhX6		 >150	 <5	 <5	
DpNEt	 >150	 >150	 >150	
RMB005	 <5	 <5	 <5	
RMB059	 <5	 <5	 <5	
RMB060	 nd	 nd	 nd	
Reserpine	 135	 5	 <5	





WHN012	 (pKa	 5.65/13.7),	 AD01	 (pKa	 3.96)	 and	 DpNEt	 (pKa	 2.38/11.3)	 had	 similar	






µM),	 and	high	 solubility	at	pH	2	 (>150	µM).	This	was	evidently	 due	 to	 the	 compound	
existing	in	the	protonated	conjugate	acid	form	at	lower	pH.	The	decoquinate	derivatives	
































and	 is	 slightly	 less	 lipophilic	 than	 artemisinin	 (LogP	 2.9)263	 and	 its	 semi-synthetic	








end	 of	 the	 ideal	 range	 (LogD7.4	 1.0),	 while	 the	 LogD	 of	 DpNEt	 (pKa	 2.38/11.3)	 was	







































































plasma	with	 only	 21%	 remaining	 after	 3	 hours.	 PhX6,	 DpNEt,	 and	RMB005	had	 good	
stability	 and	 >150	 minutes	 half-life	 in	 plasma,	 comparable	 to	 the	 reference	 control	
vinpocetine.	 RMB059	 and	 RMB060	 were	 unstable	 in	 plasma	 and	 half-lives	 were	
calculated	as	66	min	and	<8	min,	 respectively.	 Some	 functional	 groups	are	 ‘soft	 spots’	














introduced	 into	 systemic	 circulation,	 it	 would	 be	 rapidly	 converted	 to	 DQ.	 	 This	 was	
however	 thought	 to	 be	 advantageous	 as	DQ	 is	 poorly	 absorbed	and	 if	 RMB	presented	
improved	 absorption,	 it	 could	 act	 as	 “prodrug”	 for	 DQ	 delivery.	 	 This	 effect	may	 also	
improve	 the	 efficacy	 profile	 of	 these	 quinolones	 as	 there	 will	 be	 both	 parent	 and	
converted	active	metabolite	in	circulation	to	increase	the	extent	and	duration	of	efficacy.			





The	 non-specific	 binding	 of	 compounds	 to	 plasma	 proteins	was	 investigated	 using	 an	
ultracentrifuge	 method.	 As	 discussed	 in	 the	 previous	 section,	 AD01,	 RMB059,	 and	




























WHN012	 was	 highly	 bound	 to	 plasma	 proteins	 (98%)	 similar	 to	 that	 of	 mefloquine	
(98%)244	 while	 PhX6,	 DpNEt	 and	 RMB005	 were	 only	 moderately	 bound	 (Table	 3-7).		
Navaratnam	et	al.	determined	that	artemisinin	and	its	derivatives	are	moderately	bound	





Microsomal	protein	binding	was	determined	by	 incubation	 in	mouse	and	human	 liver	
microsomes,	 using	 the	 same	 ultracentrifugation	 method	 described	 in	 Section	 3.3.4.5.	




















however,	 more	 likely	 to	 bind	 extensively	 to	 microsomal	 protein.249	 DpNEt	 had	 low	
binding	 and	 RMB005	 was	 highly	 bound	 to	 microsomal	 proteins.	 No	 significant	













Mouse	 >63	 30	-	60	 <27	




to	 artesunate	and	artemisinin	 (12.3	and	 9.8	mL/min/kg,	 respectively)276	 and	 suggests	
that	WHN012	would	be	cleared	at	an	intermediate	rate	in	humans.	Intermediate	hepatic	
clearance	was	predicted	for	WHN012	in	mice.	PhX6	and	DpNEt	presented	similar	intrinsic	
clearance	values	that	were	 longer	 in	 the	mouse	but	 shorter	 in	 the	human	species,	 and	




























WHN012	 Mouse	 2	 2485	 49.1	 0.55	
	 Human	 3	 531	 11.8	 0.57	
AD01	 Mouse	 2	 772	 80,6*	 0.47*	
	 Human	 27	 74	 16.2*	 0.44*	
PhX6	 Mouse	 9	 446	 88.2	 0.98	
	 Human	 23	 82	 20.2	 0.98	
DpNEt	 Mouse	 14	 416	 22.3	 0.25	
	 Human	 34	 62	 4.00	 0.19	
RMB005	 Mouse	 55	 104	 81.2	 0.90	
	 Human	 85	 4	 12.6	 0.61	
RMB059	 Mouse	 22	 457	 75.2*	 0.46*	
	 Human	 10	 410	 19.7*	 0.49*	
RMB060	 Mouse	 17	 541	 77.2*	 0.46*	
	 Human	 12	 183	 18.6*	 0.47*	
Midazolam	 Mouse	 6	 1895	 49.0a	 0.54	
	 Human	 9	 794	 14.2a	 0.69	
MMV390048	 Mouse	 92	 11	 nd	 0.11	
	 Human	 95	 3	 nd	 0.14	
Propranolol	 Mouse	 3	 632	 62.0b	 0.69	








The	 most	 important	 drug-like	 properties	 of	 the	 compounds	 relating	 to	 the	 different	
phases	 of	 ADME	 once	 it	 enters	 a	 living	 system,	 were	 determined	 from	 the	 assays	
performed	in	this	study.	




Solubility	 was	 measured	 in	 aqueous	 buffer	 at	 pH	 2,	 which	 represents	 the	 pH	 of	 the	
stomach	 (1.4–2)	 and	 pH	6.5	 and	 7.4	which	 represents	 the	 pH	 of	 the	 intestine,	 where	
absorption	 takes	 place	 (6.8–8).278	 WHN012,	 RMB005	 and	 RMB060	 exhibited	 low	





elicit	 their	mechanism	of	 action	 by	 accumulation	 in	 such	 compartments.	Although	 the	
cytosolic	pH	of	infected	erythrocytes	is	not	significantly	different	to	normal	cells	(pH	7.4),	
other	compartments	with	a	lower	pH,	such	as	the	acidic	food	vacuole	of	the	parasite	(pH	
4.9–5.0)	 is	 important	 when	 considering	 solubility-performance	 of	 a	 drug.280	 This	 is	
demonstrated	 by	 CQ,	 a	 basic	 drug,	 that	 accumulates	 in	 the	 digestive	 vacuoles	 of	 P.	
falciparum.281		
As	 PhX6	 is	 a	 weak	 base,	 it	 was	 expected	 that	 solubility	 would	 be	 optimal	 in	 low	 pH	
environments.	This	was	demonstrated	by	high	solubility	at	pH	2	(>150	µM,	Table	3-1).	
PhX6	showed	poor	solubility	at	pH	6.5	and	7.4.	However,	the	observation	that	PhX6	has	










It	 is	 suggested	 as	 a	 rule	 of	 thumb	 that	 hydrophobicity	 is	 inversely	 correlated	 to	
hydrophilicity.283	This	was	demonstrated	by	some	of	the	compounds	investigated	in	this	
study,	particularly	through	the	high	solubility	and	below-ideal	lipophilicity	observed	for	




Permeation	 is	 largely	 controlled	 by	 the	 physicochemical	 properties	 of	 a	 drug,	 namely	
lipophilicity,	charge,	and	size	of	the	compound.	Furthermore,	the	extent	of	absorption	may	
be	 substantially	 impacted	 by	 various	 transporter	 proteins	 such	 as	 P-glycoprotein.284	
Although	WHN012	was	poorly	soluble	at	pH	6.5,	small	amounts	going	into	solution	could	
be	able	to	permeate	the	phospholipid	layer	very	well.	
In	 a	 study	 carried	 out	 by	 Senarathna	 et	 al.,	 it	 was	 demonstrated	 that	 artemisinin-
derivative	artesunate	had	moderate	permeability;	 it	was	proposed	that	 it	would	suffer	
incomplete	absorption	 in	the	GIT	as	passive	diffusion	was	not	 the	main	mechanism	of	
absorption.270	 In	 contrast,	 AMS	 has	 a	 similar	 high	 passive	 diffusion	 (LogPapp	 -4.2)	 to	
WHN012	 and	 was	 found	 not	 to	 be	 subject	 to	 P-glycoprotein-	 (P-gp)	 mediated	 efflux	
transport.270	The	PAMPA	assay	is	unable	to	distinguish	whether	compounds	like	AD01,	
with	 high	 solubility	 and	moderate	 permeability,	 are	dependent	 on	 active	 transcellular	
transport;	 or	 to	what	 extent	 it	 could	 be	 subject	 to	 P-gp	mediated	 efflux.	 It	 is	 evident	
through	 this	 example,	 that	 solubility	 and	 lipophilicity	 are	 opposing,	 inversely	 related	













The	 information	obtained	 from	the	kinetic	solubility	and	permeability	 studies	of	 these	
compounds	can	be	arranged	in	a	relationship	described	as	the	biological	classifications	
system	(BCS).	The	BCS	was	first	proposed	by	Amidon	and	colleagues285	as	a	guideline	to	




























of	 drugs	 to	 protein	 and	 tissues	 are	 common	 for	 many	 drugs	 and	 will	 impact	 the	
distribution	and	elimination.	For	antimalarial	drugs,	the	impact	of	protein	binding	is	of	
prime	 interest	because	 it	 is	 the	 free,	unbound	drug	at	 the	 site	of	 action/infection	 that	
exerts	the	therapeutic	effect.244	The	binding	to	human	plasma	proteins	of	the	compounds	
investigate	in	this	study	were	classified	as	moderately	to	highly	bound.	Downstream	in	
vivo	 investigations	 of	 potential	 candidates	 should	 be	 vigilant	 of	 differences	 in	 protein	
concentration	resulting	from	disease,	since	the	effect	of	alteration	of	drug	concentration	
of	 new	 compounds	 is	 unknown.288	 It	 is	 known	 that	 malaria	 infection	 decreases	 the	
concentration	 of	 albumin	 and	 increases	 AAG	 by	 approximately	 25%	 and	 50%,	
respectively.289	Therefore,	 the	 free	concentration	of	compounds	such	as	WHN012–that	
are	 highly	 bound	 to	 protein,	 could	 alter	 its	 therapeutic	 effectiveness	 in	 vivo.	 Another	
important	consideration	is	that	efficacious	antimalarial	therapy	is	principally	reliant	on	
combination	 therapy.	 Highly	 protein-bound	 drugs	 could	 become	 susceptible	 to	 drug	






the	 membrane	 of	 microsomes,	 where	 most	 of	 the	 metabolising	 enzymes	 reside,	 it	 is	






are	metabolised	by	enzymes	 found	 in	the	plasma	and	liver.	 If	 the	molecule	is	bound	to	
protein,	 the	 interaction	 with	 enzymes	 is	 hindered.	 This	 could	 likely	 result	 that	 the	
compounds	will	present	lower	clearance	rates	in	an	in	vivo	model.257	
The	artemisinins	are	known	to	have	metabolic	labilities	by	reductive	metabolism	of	the	





fu<0.1	 in	 human	 plasma.	 Because	 metabolic	 stability	 involving	 liver	 microsomes	 are	
predominantly	attributed	to	Phase	I	and	Phase	II	reactions,	the	low	predicted	clearance	




leaving	 it	 unavailable	 for	 the	 microsomes	 to	 metabolise	 and	 then	 resuspended	 upon	
precipitation	with	organic	solvent.	This	could	result	in	false	presentation	of	stability,	i.e.	
overprediction	 of	 the	 percentage	 remaining	 following	 incubation	 over	 60	 minutes.	
Metabolic	stability	of	compounds	RMB059	and	RMB060	could	be	misleading,	as	they	have	
shown	to	be	relatively	unstable	compounds	in	human	plasma	(Figure	3-3).	The	apparent	





showed	 correlation	 to	 some	 of	 the	 physicochemical	 and	 biochemical	 characteristics	













biological	 activity	 from	 the	 RMB	 compounds	 could	 be	 explained	 by	 a	 prodrug-effect	
whereby	compounds	were	added	to	the	incubation	plate	and	are	converted	into	the	more	
stable	parent	DQ	during	antiplasmodial	screening	assays.	High	biological	activity	of	the	






permeability.	 While	 biochemical	 properties	 included	 stability	 and	 protein	 binding.	 As	
expected,	profiles	were	significantly	different	for	each	of	the	compounds.		




in	 solution	 in	 order	 to	 produce	 the	 pharmacological	 effect.	 This	 observation	 was	 an	
example	 of	 the	 potency	 and	 permeability	 being	 dependent	 on	 minimum	 required	
solubility	 and	 should	 be	 taken	 into	 consideration	 as	 it	 may	 ultimately	 influence	 oral	
dosing	concentrations.140,293		
Lipophilicity	and	permeability	correlated	well,	and	it	was	expected	that	those	with	high	




























In	 the	 previous	 chapter	 the	 determination	 of	 the	 ADME	 properties	 of	 the	 amino-
artemisinin	 WHN012,	 the	 ethyl	 analogue	 AD01	 of	 MB,	 the	 phenoxazine	 PhX6,	 the	




systems	 are	 interrelating.294	 In	 vivo	 models	 area	 also	 able	 to	 provide	 much	 more	
information	 on	 a	 drug’s	 oral	 BA,	 duration	 of	 exposure,	 systemic	 clearance	 (CL)	 and	
distribution,	 as	 discussed	 later.	 The	murine	model	 for	 pharmacokinetic	 investigations	
offer	a	comprehensive	and	inexpensive	evaluation	of	novel	compounds	in	a	living	system.	
However,	 variability	 resulting	 from	 species	 differences	 should	 be	 kept	 in	 mind.	 For	
example,	protein	binding	can	differ	across	species	and	therefore	it	is	crucial	to	evaluate	
protein	 binding	 in	 all	 species	 of	 animals	 used	 during	 pre-clinical	 investigation.295	
Furthermore,	 concentration	 measurements	 at	 some	 sample	 collection	 sites	 can	 differ	
between	mice	and	humans.	For	example,	drugs	can	penetrate	epithelial	 lung	 fluid	to	a	












clearances.300	 Various	 organs	 are	 responsible	 for	 elimination	 of	 drugs	 including	 the	








dividing	 the	administered	dose	by	 the	area	under	 the	 concentration-time	curve	and	 is	
expressed	as	volume	per	unit	 time	 (Equation	4-2,	 Figure	4-1).300	 CL	 is	 usually	 further	
defined	as	blood,	plasma,	or	free	drug	CL	and	their	use	is	dependent	on	the	concentration	
of	drug	used.		
The	 t1/2	 of	 a	 drug	 is	 dependent	 on	 both	 the	 plasma	 CL	 and	 extent	 of	 distribution.	
Therefore,	different	drugs	may	present	similar	CL	rates	but	distinctly	different	half-lives,	
as	their	degree	of	distribution	will	influence	the	rate	at	which	they	are	eliminated	from	













following	 different	 routes	 of	 administration	 and	 is	 a	 good	 indicator	 of	 the	 extent	 of	
absorption	from	the	site	of	administration	to	the	systemic	circulation.303	The	BA	of	a	drug	
which	is	administered	via	intravenous	route,	is	assumed	to	be	100%,	as	the	bolus	dose	is	





first	 pass	 extraction	 of	 the	 drug	 via	 the	 gut	wall	 during	 absorption	 or	 through	 efflux	
 
97 
transporters	 located	 in	 the	 intestinal	 epithelium	 or	 hepatocytes.251	 Absolute	 BA	 is	
calculated	from	the	dose-corrected	area	under	the	curve	for	an	extravascular	(oral)	dose	
and	an	intravenous	dose	and	expressed	as	a	percentage	(Equation	4-5,	Figure	4-1).	













drug.	 Compounds	 that	 are	 readily	 absorbed,	 but	 survive	 major	 metabolism	 by	 liver	
enzymes,	are	likely	to	have	a	prolonged	t1/2	resulting	in	substantial	exposure.154		
Importantly,	 understanding	 the	 PK	 in	 relationship	 with	 pharmacodynamics	 of	 the	












approached	 by	 quantifying	 DQ	 as	 a	 product	 of	 the	 compounds	 administered,	 by	
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(approval	number	 013/028)	 in	accordance	with	 the	South	African	National	 Standards	








cycle.	The	cage	 floor	was	 covered	 in	dried	wood	shavings.	Paper	 strips	and	cardboard	
tubes	were	 provided	 for	 building	material	 and	 shelter.	Mice	were	 acclimatised	 to	 the	












or	 an	 organic	 vehicle	 consisting	of	 10%	dimethylacetamide	 (DMA),	 30%	polyethylene	
glycol	400	 (PEG),	50%	polypropylene	glycol	 (PPG)	and	10%	ethanol.	Dosing	 solutions	
were	 tested	 the	 day	before	 the	 scheduled	experiment	 to	 ensure	 that	 the	 compound	 is	


















were	 anesthetised	 and	 compounds	 were	 administered	 via	 the	 penile	 dorsal	 vein.	
Intravenous	 dosing	 solution	 for	 AD01	 and	 PhX6	 consisted	 of	 100%	 Millipore	 water.	
WHN012,	DpNEt,	RMB005,	RMB059,	and	RMB060	were	prepared	in	a	solution	of	DMA,	
PEG	400,	PPG	and	ethanol	(1:3:5:1,	v/v).	Between	60–120	μL	dosing	solution	was	slowly	









all	 compounds	except	 for	WHN012.	Plasma	samples	were	prepared	 from	whole	blood	
samples	for	this	compound	because	a	reliable	extraction	method	in	whole	blood	could	not	
be	 developed,	 as	 determined	 during	 extraction	 method	 development	 (Section	 4.3.7).	
Whole	blood	samples	for	WHN012	were	collected	at	pre-determined	time	points	(0.08,	
0.25,	0.5,	1.5,	2.5,	and	4	hours)	for	both	the	oral	and	intravenous	groups	and	centrifuged	











solutions	 for	 spiking	 blank	 matrix	 were	 tested	 to	 optimize	 the	 spiking	 method	 and	
improve	reproducibility.	Weighed	amounts	of	the	compounds	were	dissolved	in	DMSO	to	
generate	solutions	at	concentrations	of	1	mg/mL,	on	the	day	of	calibration	STDs	and	QC	
preparation.	 Stock	 solutions	 of	WHN012,	 AD01,	 and	 PhX6	were	 spiked	 at	 the	 highest	




parallel	 spiking	 method	 from	 working	 solutions	 were	 used.	 Working	 solutions	 were	
prepared	in	a	spiking	solution	(1:1	mix	of	mobile	phases,	v/v)	from	freshly	prepared	stock	

























PK	 analysis	 requires	 reliable	 and	 selective	 extraction	 methods	 to	 be	 developed	 and	
optimized	 for	 biological	 matrices	 prior	 to	 analysis.	 Various	 extraction	 methods	 from	






acetate.	 The	 plasma	 samples	 (15	µL)	were	 vortexed	with	 35	µL	 buffer	 containing	 an	
appropriate	 concentration	 of	 the	 ISTD	 and	 350	 µL	 ethyl	 acetate	 for	 2	 minutes.	 The	
samples	 were	 centrifuged	 at	 5590	 g	 for	 5	 minutes.	 The	 organic	 phase	 (300	 µL)	 was	
transferred	 to	 clean	polypropylene	 test	 tubes	 and	was	evaporated	 to	dryness	under	a	
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was	 precipitated	 with	 100	 µL	 ice	 cold	 organic	 solvent	 (Table	 4-2)	 containing	 an	
appropriate	 concentration	 of	 the	 ISTD	 and	 vortexed	 for	 1	 minute.	 Following	
centrifugation	at	5590	g	for	5	minutes,	50	µL	of	the	supernatant	was	transferred	to	a	96-
well	analysis	plate.	Fifty	microliters	of	aqueous	mobile	phase	were	added	to	the	samples	




Table	 4-2:	 Summary	 of	 optimized	 extraction	 methods	 from	 biological	 matrices	 and	
recovery	
Compound	 Matrix	 Extraction	method	 Mean	%	recovery	(%	CV)	
WHN012	 Plasma	 LLE	(pH	8)	 112	(3.9)	
PhX6	 Whole	blood	 PPEa	 95	(2.3)	
AD01	 Whole	blood	 PPEa	 106	(8.6)	
DpNEt	 Whole	blood	 PPEa	 88	(11.3)	
RMB005	 Whole	blood	 PPEb	 62	(0.1)	



















The	 validation	 guidelines	 from	 the	 FDA258	 and	 EMEA259,	 as	 referred	 to	 in	 Chapter	 3,	
suggest	 that	 bioanalytical	 methods	 used	 during	 preclinical	 development	 should	 be	
validated	as	FFP.	The	validation	of	sample	handling,	processing,	and	analysis	during	PK	
experiments	 were	 done	 to	 ensure	 reliability	 of	 the	 results.	 The	 following	 validation	







same	 optimised	 quantitative	 LC-MS/MS	 analytical	 methods	 described	 in	 Appendix	 C.	
Quantification	of	the	analytes	(metabolites)	was	done	using	quadratic	regression	of	peak	
area	 ratio	 versus	 concentration	 with	 1/concentration	 (1/x)	 weighting.	 Experimental	
sample	concentrations	were	calculated	from	the	calibration	curve.	All	calibration	curves	





obtained	 from	 the	 calibration	 curves	 were	 used	 during	 non-compartmental	 analysis	
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The	 seven	 compounds	 were	 administered	 orally	 and	 intravenously	 to	 healthy	 mice.	




































Mouse	 Human	 Mouse		 Human	









more	 promising	 data,	 this	 would	 have	 warranted	 a	 follow-up	 24-hour	 PK	 study.	 The	






















Following	 single	 oral	 administration	 of	 50	 mg/kg,	 the	 plasma	 concentration	 rapidly	
increased	 to	 a	 Cmax	 of	 2.32	 µM	 after	 30	minutes	 (Tmax).	 The	 plasma	 concentration	 of	
WHN012	remained	above	the	in	vitro	IC50	for	at	least	4	hours	as	indicated	in	Figure	4-2a	
and	b.	The	mean	area	under	the	curve	(AUC0-¥)	was	289	±	31	min∙µmol/L.		








PK	 profile.	 Although	 the	 predicted	 solubility	 at	 physiological	 pH	 could	 have	 limited	
intestinal	absorption	of	WHN012,	the	compound	was	rapidly	absorbed,	as	indicated	by	
the	 Tmax,	 owing	 to	 ideal	 lipophilicity	 and	 permeability	 properties.	 The	 AUC’s	 from	
intravenous	and	oral	dosing	were	 low,	considering	 the	high	dosing	concentration.	The	




the	 point	 at	 which	 absorption	 of	 WHN012	 was	 greater	 than	 the	 distribution	 and	
elimination,	 is	 an	 important	 parameter	 to	 consider,	 as	 it	 could	 indicate	 if	 plasma	
concentration	 levels	 could	 cause	 toxicity,	 especially	 from	 higher	 doses.	 Fortunately,	
WHN012	had	high	selectivity	(SI>1000)	towards	parasites,	as	the	compound	expressed	
very	low	general	toxicity	(IC50	>200	µM).		









Phase	 I	 metabolism;	 as	 has	 previously	 been	 demonstrated	 in	 other	 fluorinated	
artemisinin	derivatives	as	well	as	quinine	derivatives.314–318	Unfortunately,	the	use	of	the	
p-fluorophenyl	 group	 in	 WHN012	 did	 not	 have	 a	 marked	 effect–the	 compound	 still	
presented	moderate	to	high	CL.	The	hepatic	CL	predicted	from	the	in	vitro	 intrinsic	CL	
(49.1	 mL/min/kg)	 was	 slightly	 lower	 than	 the	 observed	 CL.	 In	 addition,	 the	 in	 vivo	
intrinsic	 CL	 of	 the	 unbound	 fraction	 (CLint,u)	 was	 calculated–as	 this	 offers	 the	 most	
accurate	interpretation	of	CL.251	The	actual	CLint,u	value	of	2950	mL/min/kg,	so	derived,	
suggested	that	CL	was	in	fact	much	faster,	as	was	predicted	from	the	metabolic	stability	
assays	 described	 in	 Chapter	 3.	 Although	 plasma	 protein	 binding	 was	 determined	 in	
human	 plasma,	 it	 offered	 valuable	 insights	 in	 the	 interpretation	 of	 PK	 data,	 as	
demonstrated	by	the	in	vivo	CLint,u.	
The	elimination	trend	of	the	intravenous	profile	in	Figure	4-2a	suggested	that	WHN012	
expressed	 first	 order	 elimination	 kinetics,	 by	 which	 a	 constant	 fraction	 of	 drug	 is	
eliminated	per	unit	time.	The	AUC0-¥	indicates	the	total	exposure	of	the	compound	in	the	
system.	By	comparing	the	intravenous	and	oral	profiles,	the	oral	AUC0-¥	is	lower	than	that	
of	 the	 intravenous.	 This	 suggests	 that	 poor	 solubility,	 as	 characterized	 during	 in	 vitro	
ADME	evaluations	(Section	3.4.1),	could	significantly	hamper	absorption	of	WHN012.	In	




administration.	 It	 is	 also	 important	 to	 consider	 that	 extraction	 by	 the	 gut-wall	 could	
potentially	contribute	to	the	low	AUC	values.251		
The	intravenous	profile	of	WHN012	incorporates	a	high	Vd,	indicating	that	the	compound	
distributes	 to	 the	 tissues	 and	 other	 compartments.	 In	 relationship	 to	 the	 lipophilicity	
(LogD7.4	 1.94)	 and	 high	 protein	 binding	 (fu	 0.02)	 determined	 from	 the	 in	 vitro	





























Mouse	 Human	 Mouse		 Human	
AD01	 >150/>150
/>150	




net	molecular	mass	of	340.5	 g/mol.	As	a	 result,	 the	 net	 concentration	 of	 AD01	 ‘active	
compound’	 upon	 dosing	 was	 calculated	 as	 18.1	 mg/kg	 and	 4.6	 mg/kg	 for	 oral	 and	

































which	 the	 signal	 fell	 below	 the	 limit	 of	 quantitation	 (7.80	 ng/mL).	 An	 apparent	
elimination	t1/2	of	2.51	hours	was	calculated,	which	was	reflective	of	the	rapid	rate	of	CL	
(74.41	 mL/min/kg).	 The	 apparent	 Vd	 was	 16.24	 L/kg	 and	 AUC0-∞	 was	 186	 ±	 15	
min∙µmol/L.	Consequently,	a	low	BA	of	15%	was	observed	for	AD01.	
The	 overall	 in	 vivo	 PK	 profile	 of	 AD01	 correlated	 well	 with	 the	 in	 vitro	 ADME	
characteristics.	 It	was	predicted	 that	AD01	would	present	high	 solubility	at	 a	 low	and	
physiological	pH	levels,	low	partitioning	to	lipid	environments	(LogD	<	1)	and	low	passive	
transcellular	 permeability.	 Lipophilicity	 and	 permeability	 influence	 the	 extent	 of	
absorption	from	the	oral	dose.	The	low	Cmax	value	observed	from	oral	dosing	(Table	4-6)	





to	 the	 predicted	 CL,	 both	 indicating	 that	 AD01	 was	 rapidly	 cleared	 from	 the	 system.	
Unfortunately,	 intrinsic	 in	 vivo	 CL	 values	 could	 not	 be	 reported,	 as	 determination	 of	
protein	binding	was	not	possible	for	AD01.	
AD01	was	 unstable	 during	 investigation	 of	 stability	 in	 human	 plasma	 (Section	 3.4.4),	
which	suggested	non-CYP	biotransformation	potentially	contributed	to	the	metabolism	

















unable	 to	remain	above	the	 IC50,	more	 frequent	dosing	would	be	 required	 to	maintain	
potentially	therapeutic	levels.		
With	the	above	in	mind,	the	effective	combination	of	AD01	with	a	fast-acting	artemisinin	
and	 potentially	 a	 third	 partner	 quinolone,	 could	 remain	 beneficial	 in	 the	 redox	 drug	
combination	rationale.	AD01	presented	a	high	apparent	Vd	(16.24	±	1.73	L/kg,	Table	4-
6),	 similar	 to	MB.	 In	 a	 study	 carried	 out	 by	 Peter	 et	 al.,	 the	 PK	 profile	 of	MB	 and	 its	
distribution	into	organs	in	rats	was	established.	It	was	found	that	MB	was	subjected	to	
extensive	 ‘first-pass	 distribution’	 to	 the	brain,	 intestinal	wall,	 liver,	 and	 bile,	 following	
intravenous	 and	 intraduodenal	 administration.322	 The	 researchers	 concluded	 that	 this	
was	a	likely	reason	for	large	difference	in	the	observed	AUC	values.		































Mouse	 Human	 Mouse		 Human	
PhX6	 >150/<5/	
<5	
1.0	 -4.4	 >150	 90	 99	 99	 88.2	 20.2	
	
The	phenoxazine	derivative	PhX6	was	administered	orally	(n=5)	and	intravenously	(n=5)	










































high	 solubility	 at	 pH	 2.	 The	 physiological	 pH	 range	 of	 the	 intestinal	 environment	 is	













The	 microsomal	 assays	 predicted	 extensive	 liver	 metabolism	 (CLH	 88.2	 mL/min/kg).	
However,	 this	 was	 not	 observed	 in	 the	 mouse	 PK	 study	 (21.47	 ±	 1.76	 mL/min/kg).	
Additionally,	 the	 derived	 CLint,u	 suggested	 a	 much	 faster	 CL	 (214.7	 mL/min/kg).	 The	
elimination	phase	of	PhX6,	as	 indicated	 in	Figure	4-4a,	shows	multiphasic	elimination.	
Following	 intravenous	 administration,	 PhX6	 presented	 a	 long	 t1/2	 of	 approximately	 8	
hours.	Compounds	with	longer	half-lives	are	favoured	for	use	in	combination	with	faster	
acting,	 short	 t1/2	 drugs.	 The	 AUC	 obtained	 from	 oral	 administration	 shows	 that	 the	
compound	is	significantly	absorbed	in	the	bloodstream.	This	suggested	that	PhX6	can	be	
maintained	in	the	system	and	offers	better	potential	to	elicit	its	pharmacological	effect.	
Therefore,	 greater	 exposure	 of	 a	 drug	 in	 the	 system	 could	 translate	 to	 greater	
concentrations	 of	 the	 compound	 available	 at	 the	 therapeutic	 site	 of	 action.36	

































Mouse	 Human	 Mouse		 Human	
DpNEt	 >150/>150
/>150	
2.3	 -3.7	 >150	 94	 16	 25	 22.3	 4.00	
	
The	 thiosemicarbazone	 derivative	 DpNEt	 was	 administered	 orally	 (n=5)	 and	
intravenously	 (n=5)	 as	 described	 in	 Section	 4.3.4.	 The	 experimental	 samples	 were	


































observed	 across	 all	 pH	 levels	 tested	 (>150	 µM),	 as	 well	 as	 high	 apparent	 passive	
transcellular	permeability	(LogPapp	-3.7).	DpNEt	also	expressed	ideal	lipophilicity	in	the	




predicted	 hepatic	 CL	 obtained	 from	 in	 vitro	 metabolic	 stability	 assays	 (CLH	 22.3	






Three	 physiological	 processes	 are	 involved	 during	 CL	 of	 xenobiotics	 from	 the	 system	
namely	 metabolic	 transformation,	 renal	 excretion,	 and	 hepatobiliary	 excretion.	 The	
physiochemical	properties	of	a	compound	may	give	indications	of	which	rate-determining	
mechanism	 would	 be	 favoured.	 In	 the	 case	 of	 a	 lipophilic	 compound,	 metabolic	
transformation	 by	 the	 liver	 is	 favoured,	whereas	 hydrophilic	 or	 polar	 compounds	 are	
more	likely	to	be	cleared	by	active	or	passive	excretion.251		
The	hydrophilicity	and	polar	nature	of	DpNEt	in	conjunction	with	the	in	vivo	parameters	
suggest	 that	 the	route	of	elimination	of	DpNEt	is	more	likely	 to	be	via	hepatobiliary	or	


























































Mouse	 Human	 Mouse		 Human	






































The	 in	 vivo	 profile	 of	 RMB005	 correlates	 well	 with	 the	 predicted	 in	 vitro	 ADME	
parameters	in	terms	of	solubility	and	exposure.	Although	RMB005	was	quickly	absorbed,	
the	 extent	 of	 exposure	 was	 limited–presumably	 by	 the	 poor	 solubility	 (<5	 µM).	 The	
dynamic	state	of	equilibrium	at	which	solubility	functions	in	a	living	system,	as	described	
in	 Chapter	 3,	 likely	 did	 not	 favour	 membrane	 permeability	 of	 the	 small	 amount	 of	
compound	that	was	available	in	solution,	as	the	passive	permeability	was	also	very	low	
(LogPapp	-6.3).	Consequently,	the	low	AUC	observed	following	oral	dosing	is	an	intricate	






































Mouse	 Human	 Mouse		 Human	
RMB059	 <5/<5/<5	 2.9	 -5.8	 66	 nd	 nd	 nd	 75.2	 19.7	
RMB060	 nd	 2.9	 -6.3	 <8	 nd	 nd	 nd	 77.2	 18.6	
	
As	discussed	 in	Chapter	2,	RMB059	and	RMB060	were	synthesised	 from	DQ	as	newer	
decoquinate	 derivatives.	 These	 compounds	 were	 introduced	 and	 investigated	
subsequently	to	RMB005.	The	aim	in	this	investigation	was	to	establish	if	RMB059	and	
RMB060	had	improved	PK	profiles	in	terms	of	solubility,	stability	and	exposure	relative	
to	 RMB005.	 RMB059	 and	RMB060	were	 administered	 orally	 (n=3)	 and	 intravenously	
(n=3)	as	described	in	Section	4.3.4.		






whole	 blood	 which	 suggests	 that	 they	 would	 be	 labile	 as	 soon	 as	 being	 inserted	 or	
absorbed	into	the	systemic	circulation,	and	potentially	be	hydrolysed	in	the	stomach.		
The	 validation	 of	 bioanalytical	 methods	 of	 DQ	 are	 summarised	 in	 Appendix	 D.	 NCA	
analysis	of	DQ	(as	metabolite	of	RMB059	and	RMB060)	was	carried	out	(Table	4-14	and	
4-15,	 respectively).	 The	 whole	 blood	 concentration	 profiles	 of	 DQ	 obtained	 from	

























































4-7B,	where	after	 it	 slowly	 declined.	The	whole	blood	 concentrations	 of	DQ	remained	
above	the	IC50	(0.026	µM)	for	at	least	8	hours,	after	which	the	concentrations	fell	below	
the	lower	limit	of	quantitation	(LLOQ).	The	mean	AUC0-∞	was	101	±	44	min∙µmol/L.	The	
elimination	 t1/2	 was	 4.79	 hours	 and	 CL	 of	 DQ	 was	 relatively	 slow	 (19.40	 ±	 3.14	















the	 exceptionally	 poor	 solubility	 of	 DQ	 in	 water229	 further	 limited	 the	 extent	 of	 DQ	
absorption.	From	this,	it	can	be	concluded	that	the	ethyl	ester	carbamate	quinolone	DQ	







As	 described	 in	 Chapter	 3,	 bioanalytical	 assays	 used	 during	 preclinical	 investigation	
should	be	robust,	accurate,	and	precise,	and	validated	according	to	“fit	for	purpose”	FDA	
guideline	 criteria.	 Validation	 of	 the	 assays	 included	matrix	 stability,	 recovery,	 matrix	
effects,	 carry	 over,	 and	 formulation	 stability.	 The	 assays	 proved	 to	 be	 robust	 and	
performed	 well	 during	 PK	 sample	 analysis.	 However,	 two	 compounds,	 RMB059	 and	
RMB060	were	exceptions	to	this	outcome,	as	they	were	found	to	be	very	unstable	in	whole	





As	 described	 in	 Chapter	 2,	 the	 rationale	 for	 development	 of	 the	 amino-artemisinin	




Haynes	et	al.	 concluded	 that	AMS	 offered	 improved	BA	and	stability	 in	 comparison	 to	
artemisinin.261,336	For	the	purpose	of	this	research	project,	AMS	should	be	considered	as	
the	oxidant	partner	in	the	in	vitro	investigations	to	follow,	for	the	fact	that	WHN012	did	





this	 study,	PhX6	had	 the	best	PK	properties	and	was	 identified	as	 the	most	successful	
compound	to	investigate	further	in	in	vitro	combination	experiments	together	with	AMS.	
















WHN012	 AD01	 PhX6	 DpNEt	 RMB005	 RMB059-DQ	 RMB060-DQ	
Intravenous	 	 	 	 	 	 	 	
	Elimination	t1/2	(h)	 1.34	±	0.28	 2.51	±	0.07	 7.96	±	0.73	 1.12	±	0.13	 2.62	±	0.61	 4.79	±	1.66	 4.66	±	1.16	
	CL	(mL/min/kg)	 58.90	±	2.01	 74.41	±	6.86	 21.47	±	1.76	 10.20	±	0.93	 28.50	±	2.17	 19.40	±	3.14	 21.50	±	3.38	
	Vd	(L/kg)	 6.92	±	1.71	 16.24	±	1.73	 14.92	±	2.09	 1.00	±	0.16	 6.59	±	1.83	 8.00	±	2.96	 8.88	±	2.87	
	AUC0-∞	(min∙µmol/L)	 347	±	11	 186	±	15	 540	±	44	 1795	±	198	 377	±	32	 573	±	98	 592	±	108	
Oral	 	 	 	 	 	 	 	
	Cmax	(µM)	 2.32	±	0.34	 0.25	±	0.05	 3.45	±	0.68	 6.32	±	1.15	 0.49	±	0.02	 0.23	±	0.05	 0.11	±	0.01	
	Tmax	(h)	 0.50	±	0.00	 0.88	±	0.13	 0.80	±	0.12	 0.70	±	0.12	 0.70	±	0.12	 1.67	±	0.67	 1.67	±	0.67	
	AUC0-∞	(min∙µmol/L)	 289	±	31	 101	±	19	 1150	±	216	 550	±	148	 59	±	2	 101	±	44	 63	±	9	















Currently,	 the	 continued	 use	 of	 first-line	 ACTs	 is	 threatened	 by	 the	 delay	 in	 parasite	
clearance	times.183	The	WHO	has	 strongly	recommended	against	 the	administration	of	




As	 described	 in	 Chapter	 1,	 the	 overarching	 goal	 of	 the	 Flagship	 Project,	 of	 which	 this	
research	 forms	part,	 is	 to	develop	new	compounds	that	 can	be	used	together	with	 the	
existing	 artemisinins,	 or	 new	 artemisinin	 derivatives	 that	 can	 protect	 the	 artemisinin	
component	from	emergence	of	resistance.		
The	partner	 compound	should	 ideally	be	 longer	acting,	have	a	different	mechanism	of	
action	 to	 the	 artemisinin	 and	 have	 a	 synergistic	 interaction.	 Extensive	 research	 on	
artemisinin	 derivatives	 have	 provided	 many	 active	 compounds,	 for	 example,		
hydroxyartemisinin	 derivatives,339	 triazolyl	 artemisinins340	 and	 endoperoxides	 which	













compounds	 and	 investigated	 as	 potential	 antimalarial	drug	 candidates,	 for	 the	 overall	
benefit	 that	the	oxidant	abruptly	induces	oxidative	stress,	which	 is	 then	maintained	or	
enhanced	by	redox	cycling	of	the	redox	drug	partner.	From	the	initial	group	of	compounds	
identified	in	Chapter	2,	two	compounds	were	selected	for	investigation	in	vitro	based	on	




The	 first	 compound	 selected	 for	 isobole	 analysis	was	PhX6.	 The	 compound	presented	






AD01	was	 selected	 for	 its	 chemical	 similarity	 to	MB,	being	 the	slightly	more	 lipophilic	




for	 their	potential	 synergistic	 interactions	 in	 vitro	as	 this	 result	 could	greatly	enhance	








ratio	 isobologram	 analysis	 originally	 described	 by	 Fivelman	 et	 al.337	 The	method	was	
adapted	and	simplified	from	the	traditional	checkerboard	assay.346	Fivelman	argues	the	
fixed	ratio	method	is	simpler,	with	easier	calculations	and	is	more	accurate	compared	to	
the	checkerboard	assay,	which	 is	affected	by	day	to	day	variations	 in	single	 initial	 IC50	
concentrations.	The	main	aim	of	the	work	described	in	this	chapter	was	to	determine	if	
an	oxidant	drug	(AMS)	together	with	a	redox	compound	(AD01	or	PhX6)	would	produce	




















Parasite	 culturing	 methods	 and	 parasite	 survival	 assay	 methods	 are	 described	 in	






PhX6	 or	 AD01	 using	 the	modified	 fixed-ratio	method	 against	 CQS	NF54	P.	 falciparum	
parasites	in	the	standard	72-hour	pLDH	assay.149		
The	two	compounds	were	tested	alone	and	in	combination	at	ratios	of	3:1,	1:1,	1:3	and	
1:9,	 and	 were	 prepared	 as	 six	 solutions	 (Table	 5-1).	 The	 first	 (C1)	 and	 last	 (C6)	
combination	 solution	 contained	either	drug	A	 (AMS)	or	drug	B	(AD01	or	PhX6)	alone.	
Compounds	were	diluted	 from	2	mM	DMSO	stock	solutions	and	combination	solutions	




The	 solutions	were	added	 to	 the	 sterile	 assay	 plate	and	 serial	 dilutions	were	made	 in	













	 Compound	A	 	 Compound	B	
	 AMS	 	 AD01	 or	 PhX6	
C1	 1	 0	 	 100	 	 0	 	 0	
C2	 3	 1	 	 75	 	 25	 	 200	
C3	 1	 1	 	 50	 	 50	 	 400	
C4	 1	 3	 	 25	 	 75	 	 600	
C5	 1	 9	 	 10	 	 90	 	 720	







used	 to	 generate	 sigmoidal	 dose-response	 curves	using	GraphPad	Prism	version	 5	 for	
Windows	(GraphPad	Software	Inc.,	La	Jolla,	California).	Each	data	point	obtained	from	the	
combination	samples	was	represented	in	two	data	sets.	Each	combination	(C2,	C3,	C4,	and	
C5)	 was	 thus	 represented	 by	 two	 curves–one	 curve	 for	 each	 of	 the	 drugs	 in	 the	
combination	with	respect	 to	 its	 concentration	 range.	A	 single	 curve	was	generated	 for	
each	of	the	single	compounds	tested.	Therefore,	10	sigmoidal	dose-response	curves	were	














The	 IC50	 values	 were	 used	 to	 calculate	 the	 50%	 fractional	 inhibitory	 concentrations	
(FIC50)	 of	 drug	 A	 within	 the	 respective	 combination	 (Equation	 5-1),	 i.e.	 the	 extent	 of	
growth	 inhibition	 by	 the	 combination	 (drug	 A	 +	 drug	B)	 divided	 by	 the	 inhibition	 by	
application	 of	 the	 drug	 alone	 (drug	 A)	 (Equation	 5-1).	 The	 same	 was	 done	 for	 FIC50	
calculation	of	drug	B	(Equation	5-2).	The	sum	of	FICs	was	calculated	by	addition	of	FIC50	
(A)	and	FIC50	(B)	(Equation	5-3)	in	order	to	determine	the	interaction	of	the	compounds.	






































(CQS	 NF54	 23.1	 nM)	 and	 PhX6	 (CQS	 NF54	 41.8	 nM)	 were	 determined	 previously,	 as	
discussed	in	Chapter	2.	The	pLDH	parasite	survival	assay,	as	described	in	Appendix	A,	was	
used	to	determine	the	IC50	of	AMS.	An	IC50	of	4.50	±	2.42	nM	against	the	CQS	NF54	parasite	

















Figure	 5-4:	 Representative	 graph	 of	 classification	 areas	 for	 ∑FIC	 values.	 ∑FIC	













(23.31	 nM)	 alone.	 This	 indicated	 that	 these	 worked	 better	 together	 than	 as	 single	
compounds.	IC50‘s	from	the	combination	of	AMS	and	PhX6	revealed	similar	trends	with	
values	 ranging	 from	1.84	nM	 to	 0.61	nM	 for	AMS	 and	21.21	 nM	 to	3.20	 nM	 for	PhX6,	
compared	to	the	IC50	of	AMS	(2.86	nM)	and	PhX6	(45.61	nM)	alone	(Table	5-2a).		
The	 FIC50	 of	 AMS	 in	 combination	 with	 AD01	 or	 PhX6	 in	 respective	 combination	
experiments	were	used	to	calculate	the	∑FIC50’s	of	each	combination.	Isobolograms	were	
constructed	 from	 resulting	 ∑FIC50’s	 and	 curve	 shapes	 were	 observed	 to	 determine	
synergy,	 antagonism	 or	 addition.	 Both	 AMS	 +	 AD01	 and	 AMS	 +	 PhX6	 combinations	
produced	 a	 concave	 curve	 shape	 (Figure	 5-5a	 and	 5c)	 which	 indicated	 synergistic	
interactions.	 To	 clearly	 define	 interaction	 of	 two	 compounds,	 the	 ∑FIC50	 values	were	
classified	 as	 the	 following:	 values	 below	 0.8	 indicate	 synergism,	 above	 1.4	 indicate	
antagonism	and	between	0.8	and	1.4	 indicate	addition.349	∑FIC50	 ranged	between	0.61	
and	 0.71	 for	 AMS	 +	 AD01	 and	 between	 0.73	 and	 0.87	 for	AMS	 +	 Phx6.	 Therefore,	 all	
combinations	were	 classified	as	having	synergistic	 interactions,	except	 the	1:9	 ratio	of	














Drug	A		 Drug	B		 	 Drug	A		 Drug	B		
AMS	+	AD01	 1:0	 6.16	±	2.92	 nd	 	 1.00	±	0.0	 nd	 1.00	 	
	 3:1	 3.40	±	1.44	 0.92	±	0.40	 	 0.56	±	0.08	 0.04	±	0.02	 0.60	 Synergy	
	 1:1	 1.97	±	0.83	 2.04	±	0.78	 	 0.34	±	0.07	 0.09	±	0.04	 0.43	 Synergy	
	 1:3	 1.14	±	0.38	 3.63	±	1.53	 	 0.20	±	0.05	 0.16	±	0.08	 0.36	 Synergy	
	 1:9	 1.35	±	0.54	 10.35	±	2.40	 	 0.25	±	0.13	 0.46	±	0.15	 0.71	 Synergy	
	 0:1	 nd	 23.31	±	2.49	 	 nd	 1.00	±	0.0	 1.00	 	
AMS	+	PhX6	 1:0	 2.86	±	1.01	 nd	 	 1.00	±	0.0	 nd	 1.00	 	
	 3:1	 1.84	±	0.59	 3.20	±	1.34	 	 0.65	±	0.02	 0.09	±	0.05	 0.73	 Synergy	
	 1:1	 1.46	±	0.46	 7.88	±	3.67	 	 0.51	±	0.06	 0.20	±	0.09	 0.72	 Synergy	
	 1:3	 0.91	±	0.31	 14.17	±	6.13	 	 0.32	±	0.01	 0.38	±	0.20	 0.70	 Synergy	
	 1:9	 0.61	±	0.35	 21.21	±	2.22	 	 0.21	±	0.05	 0.67	±	0.17	 0.87	 Addition	








Drug	A		 Drug	B		 	 Drug	A		 Drug	B		
AMS	+	AD01	 1:0	 9.56	±	6.78	 nd	 	 1.00	±	0.00	 nd	 1.00	 	
	 3:1	 5.25	±	3.82	 1.53	±	0.88	 	 0.58	±	0.16	 0.04	±	0.02	 0.62	 Synergy	
	 1:1	 3.63	±	1.74	 3.62	±	1.76	 	 0.47	±	0.24	 0.09	±	0.05	 0.55	 Synergy	
	 1:3	 2.20	±	1.05	 7.09	±	4.62	 	 0.27	±	0.08	 0.17	±	0.11	 0.43	 Synergy	
	 1:9	 2.18	±	1.19	 15.76	±	5.01	 	 0.27	±	0.12	 0.37	±	0.15	 0.64	 Synergy	
	 0:1	 nd	 44.71	±	11.37	 	 nd	 1.00	±	0.00	 1.00	 	
AMS	+	PhX6	 1:0	 5.20	±	1.48	 nd	 	 1.00	±	0.00	 nd	 1.00	 	
	 3:1	 2.75	±	0.77	 4.94	±	2.24	 	 0.53	±	0.01	 0.08	±	0.06	 0.61	 Synergy	
	 1:1	 2.70	±	1.28	 13.63	±	5.09	 	 0.50	±	0.10	 0.20	±	0.11	 0.71	 Synergy	
	 1:3	 1.44	±	0.76	 120.52	±	5.92	 	 0.27	±	0.07	 0.33	±	0.23	 0.59	 Synergy	
	 1:9	 1.09	±	0.85	 47.38	±	8.81	 	 0.19	±	0.10	 0.65	±	0.18	 0.85	 Addition	


















fixed	 drug	 combinations	 were	 determined	 using	 the	 pLDH	 assay	 against	
intraerythrocytic	asexual	parasites	for	72	hours.	The	dashed	line	corresponds	to	an	
indifferent	interaction.	The	solid	line	indicates	the	respective	isobole	curve	of	the	














the	 in	 vitro	gametocytocidal	 effects	of	artemisinin	derivatives	may	be	augmented	with	
strategic	combination	of	MB	and	that	the	findings	encourage	further	investigation	in	order	
to	 supplement	 the	 evidence	 of	 redox	 combinations.	 The	 high	 efficacy	 of	 MB-based	
combinations207,344,351207	 strongly	 encourages	 further	 investigation	 into	 synergistic	
interaction	between	artemisinins	and	redox	compounds	like	MB.		
	
It	 was	 anticipated	 that	 synergism	between	AMS	 in	 combination	with	AD01	 and	PhX6	















the	 hypothesis	 of	 including	 redox	 compounds	 in	 artemisinin-based	 therapy,	 as	
artemisinins	are	currently	the	most	active	antimalarial	drugs	both	in	terms	of	the	dosage	














partner	 for	AMS	 than	AD01.	Although	synergistic	 activity	with	AD01	was	greater	 than	
PhX6	in	combination	ratio	1:1	and	1:3,	it	probably	will	not	be	chosen	for	further	studies.	










using	 the	modified	 fixed-ratio	method	 to	 identify	 potential	 synergistic	 interactions.337	
Both	compounds	improved	the	IC50	of	AMS	in	combination	compared	to	that	of	AMS	alone.	
The	∑FIC50’s	were	 all	 classified	 as	 predominantly	 synergistic	 and	 an	 ANOVA	 test	was	
applied	 to	 distinguish	 significant	 interactions	 according	 to	 the	 ∑FIC50’s	 of	 each	




successful	 as	 clinically	 used	 therapies.	 With	 regards	 to	 malaria,	 high	 level	 of	 efficacy	
together	with	drugs	that	have	multiple	mechanisms	and	different	elimination	half-lives	
are	 essential	 in	 overcoming	 disease	 burden	 and	 preventing	 the	 emergence	 of	
resistance.338	With	this	in	mind,	PhX6	was	 identified	as	having	the	most	favourable	PK	
profile	of	all	compounds	evaluated,	as	well	as	having	significant	synergistic	interaction	
with	 AMS.	 This	 will	 increase	 the	 potential	 of	 therapeutic	 efficacy	 of	 PhX6	 in	 vivo	 in	
combination	 with	 AMS.	 These	 findings	 strongly	 encourage	 further	 investigation	 of	










The	 effective	 treatment	 and	 control	 of	 malaria	 is	 increasingly	 threatened	 by	 the	
development	of	drug-resistant	parasites.	Drugs	that	were	once	used	 in	highly	effective	
therapies	 in	 malaria	 endemic	 areas	 have	 been	 replaced	 by	 ACTs.	 Even	 though	
artemisinins	are	the	most	rapidly	acting	and	effective	drugs,	their	efficacy	for	the	global	




As	 outlined	 in	 Chapter	 1,	 the	 concept	 underpinning	 this	 research	 is	 of	 potentiating	
oxidative	stress	within	the	parasite’s	proliferating	environment	by	combining	an	oxidant	
drug	with	a	redox	drug	capable	of	maintaining	high	levels	of	ROS	through	its	redox	cycling	






a	 multidisciplinary	 collaboration.	 These	 were	 initially	 selected	 based	 on	 their	
antiplasmodial	 activity.	 The	 compounds	 were	 artemisinin	 derivatives,	 phenoxazines,	






WHN012,	 an	 aryl	 urea	 derived	 from	 DHA-piperazine,	 was	 selected	 as	 the	 oxidant	
compound.	The	compound	showed	remarkably	good	activity	against	both	CQR	and	CQS	
parasite	 strains.	 Although	 the	 artemisinins	 are	 regarded	 the	 most	 active	 antimalarial	
drugs,	 they	are	known	to	be	very	unstable.	 It	was	expected	that	 the	electronegative	p-







WHN	 compound	 class	 certainly	 do	 justify	 their	 worth	 for	 further	 investigation	 and	
generating	yet	newer	compounds	optimised	in	terms	of	stability	and	solubility.		
AD01	is	an	ethyl	derivative	of	MB,	a	known	redox	drug.	Although	AD01	showed	excellent	
solubility,	 the	 lack	of	 lipophilicity	and	poor	passive	permeability	limited	 its	absorption	
and	contributed	 to	 low	BA	 (14%).	Poor	 stability	of	AD01	was	observed	 in	 the	plasma	
stability	assay	and	this	was	also	reflected	in	the	animal	experiments.	The	susceptibility	of	
the	 compound	 to	metabolism	may	 indicate	 that	 active	 metabolites	 are	 being	 formed.	
Future	studies	will	focus	on	this	possibility.		















showed	 that	 DpNEt	 had	 surprisingly	 low	 BA	 (8%).	 The	 predicted	 hepatic	 CL,	 in	 vivo	
systemic	CL	and	low	Vd	raised	the	question	of	whether	DpNEt	was	subject	to	other	routes	
of	 elimination.	 It	 was	 hypothesised	 that	 DpNEt,	 although	 being	 absorbed	 well,	 was	
potentially	 a	 substrate	 for	 P-gp	 transporters	 that	 could	 ultimately	 influence	
concentrations	seen	in	whole	blood.		
Lastly,	 the	 RMB	 compounds	 derived	 from	 decoquinate	 (DQ)	 were	 investigated	 as	
potential	longer	acting	third	partner	compounds	to	the	redox	cycling	combination.	The	












and	 in	 vivo	properties.	 The	 evaluation	 of	 the	 PK	 properties	 and	 in	 vitro	 combinations	
resulted	 in	 the	 identification	 of	 the	 potentially	 efficacious	 PhX6+AMS	 combination.	
Considering	 these	 results,	 it	 is	 highly	 recommended	 that	 this	 combination	 be	 further	
investigated.	
Research	 limitations	 can	 result	 in	 the	 incomplete	or	 incorrect	 interpretation	of	results	
from	a	study	and	thus	influence	downstream	research	based	on	those	data.	Firstly,	AD01	
and	DpNEt	are	suspected	to	be	subject	to	active	transport	mechanisms,	based	on	their	PK	
profiles	 obtained	 from	 the	 mouse	 model.	 For	 the	 determination	 of	 membrane	




absorbed	 and	 eliminated	 through	 other	mechanisms.278	 Although	 the	 PAMPA	 assay	 is	
considered	to	be	relatively	basic,	it	remains	the	preferred	model	in	HTS	environments	and	
is	a	more	economic	model	to	use.		
The	 general	 stability	 of	 the	 RMB	 compounds	 should	 be	 addressed.	 As	 mentioned	
previously,	 RMB059	 and	 RMB060	were	 too	 unstable	 and	whole	 blood	 concentrations	














should	be	evaluated	 in	 an	 in	 vivo	 efficacy	model	 in	order	 to	 establish	 the	 relationship	
between	PK	and	efficacy	of	the	compounds.	This	can	be	achieved	with	the	SCID	humanised	




synergistic	 in	 a	 dynamic,	 living	 system.	 Additionally,	 gametocyte	 and	 transmission-
blocking	activity	are	a	central	focus	for	drug	discovery	for	antimalarials.	In	the	efforts	to	
eradicate	malaria	this	should	be	investigated	in	potential	antimalarial	compounds	such	as	





an	 oxidant	 and	 redox-active	 drug,	 it	 should	 be	 noted	 that	 activity	 in	 resistant	 strains,	
specifically	 artemisinin	 resistant	 strains,	 also	 play	 a	 key	 role	 in	 the	 progression	 of	 a	
compound	in	preclinical	research.	This	is	a	research	objective	that	should	be	addressed	
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A	 Labcon	 508IU	 incubator	 maintained	 at	 37°C	 was	 used	 to	 store	 all	 cultures	 of	 P.	





























data	and	calculate	 statistical	 significance	 (GraphPad	Software	 Inc.,	 La	 Jolla,	California).	











(containing	 glutamine,	 but	 without	 sodium	 bicarbonate),	 4	 g/L	 D-(+)-glucose,	 6	 g/L	
HEPES,	0.088	g/L	Hypoxanthine,	5	g/L	Albumax	and	0.05	g/L	gentamycin.	The	medium	































































The	 solution	 was	 pre-filtered	 (0.45	 µm	 filter)	 and	 then	 filter	 sterilized	 through	 a	
membrane	(0.22	μm)	into	autoclaved	glass	bottles.		
Incomplete	HAMS	F-12	medium	was	prepared	by	adding	one	bottle	of	HAMS	F-12	to	1	L.	
The	 solution	was	 stirred	 for	 30	minutes	 and	 the	 pH	 adjusted	 to	 7.1.	 Lastly,	 500	 μl/L	









































Cultures	 were	 maintained	 under	 sterile	 conditions	 throughout	 cultivation	 process	 in	
washed	O+	human	RBC	at	a	5%	haematocrit	in	CM.	CQS	and	CQR	strains	were	cultured	









clean	 flat-bottomed	culture	 flask.	 In	 the	case	of	a	predominantly	 ring	 culture,	 the	 cells	
were	 incubated	 on	 the	 bench	 with	 10	 mL	 sorbitol,	 according	 to	 Lambros	 and	











highest	 concentration	 into	 the	 adjacent	well,	 containing	 equal	 volume	 of	 CM.	 A	 stock	







Plates	 were	 frozen	 at	 overnight	 -80°C	 after	 completion	 of	 the	 incubation	 period	 and	



























to	the	 flask	to	 inhibit	 the	Trypsin.	The	culture	was	transferred	to	sterile	15	mL	Falcon	











































































































A	Satorius	CPA2P	Micro-Analytical	Balance	was	 used	 to	weigh	out	 all	 compounds	and	
standards.	
Ultracentrifuge	













































































organic	 mobile	 phase.	 The	 organic	 phase	 consisted	 of	 a	 0.1%	 formic	 acid	 solution	 in	
acetonitrile	(ACN).		
Preparation	of	mobile	phases	for	LC-MS/MS	analysis	
Aqueous	 and	 organic	 solutions	 were	 prepared	 for	 each	 compound	 identified	 during	
method	 development.	 Aqueous	 mobile	 phases	 consisted	 of	 either	 0.1%	 formic	 acid	































































































 +MS2 (341.00) CE (35): 26 MCA scans from Sample 1 (TuneSampleName) of AD01_InitProduct_Pos.wiff (Turbo Spray) Max. 6.4e5 cps.




















































 -MS2 (475.22) CE (-50): 26 MCA scans from Sample 1 (TuneSampleName) of RMB 005 0125 NEG_InitProduct_Neg.wiff (Turbo Spray) Max. 2.0e5 cps.

























































(RT).	 Reversed	 phase	 gradient	 chromatography	 was	 superior	 to	 isocratic	







for	 the	 organic	 phase,	 similar	 to	 previously	 described	 methods.355,356	WHN012	 had	 a	
retention	 time	 of	 approximately	 3.3	 min	 and	 the	 total	 run	 time	 was	 7	 min.	 During	













retention	 of	 RMB059.	 The	 ideal	 elution	 range	 lies	 within	 the	 gradient	 or	 in	 the	 high	
organic	phase	of	the	gradient.	Polar	compounds	will	elute	early	and	result	in	possible	ion	
suppression.	Elution	beyond	the	high	non-polar	phase	could	also	result	 in	possible	ion	
suppression,	 as	 lipids	 and	 other	 hydrophobic	 background	 molecules	 will	 elute	 late.	









































































490	→	224	 100	 46	 9	 17	 4	
490	→	163	 100	 46	 9	 27	 6	
PhX6	
395	→	351	 150	 131	 9	 31	 6	
	395	→	78.2	 150	 131	 9	 77	 6	
AD01	
341	→	297	 150	 61	 11	 47	 6	
341	→	253	 150	 61	 11	 71	 12	
DpNEt	
286	→	241	 150	 46	 5	 15	 6	
286	→	183	 150	 46	 5	 12	 6	
RMB005	
475	→	334	 150	 -110	 -10	 -34	 -4	
475	→	277	 150	 -110	 -10	 -58	 -4	
RMB059	
531	→	114	 150	 111	 9.5	 41	 2	
	531	→	71.2	 150	 111	 9.5	 69	 2	
RMB060	
608	→	204	 150	 121	 12	 85	 4	
608	→	372	 150	 121	 12	 36	 4	
DQ	
418	→	372	 150	 56	 11	 29	 6	













XIC of +MRM (6 pairs): 341.000/297.300 Da  from Sample 11 (S2) of 1001.wiff (Turbo Spray) Max. 1.5e4 cps.

























AD01:  341.000            297.300
(quantifier)
XIC of +MRM (6 pairs): 341.000/253.200 Da  from Sample 11 (S2) of 1001.wiff (Turbo Spray) Max. 1.2e4 cps.





















































































































in	 Chapter	 3	 and	 Chapter	 4.258,259	 To	 adequately	 assess	 possible	 variabilities	 or	
interferences	 with	 accurate	 measurement	 of	 analytes,	 certain	 parameters	 have	 been	
tested	 in	 order	 to	 ensure	 reproducibility	 and	 accuracy	 of	 the	 data	 generated	 in	 this	
project.	 These	 parameters	 included	 linearity,	 accuracy,	 precision,	 stability,	 carryover,	
matrix	effects,	and	extraction	efficiency.	
Linearity	









to	 demonstrate	 accuracy	 and	 precision	 of	 samples	 with	 known	 concentrations.	 It	 is	





































nominal,	 true	 concentration	 value	 (accuracy)	 and	 if	 the	 degree	 of	 variation	 between	
replicates	(precision)	is	within	an	acceptable	range.		
Quantification	 accuracy	 and	 precision	were	measured	 for	 the	 calibration	 range	 of	 the	
standard	 curve,	 as	 well	 as	 high,	 medium,	 and	 low	 concentration	 QCs	 of	 all	 analytes.	









Compound	 Transition	 Accuracy	(%)	 CV	(%)	
WHN012	 490.312	!	224.200	 91.4	–	109.2	 5.68	
AD01	 341.000	!	297.300	 91.2	–	104.7	 17.8	
PhX6	 395.219	!	351.400	 96.3	–	106.2	 10.4	
DpNEt	 286.165	!	241.300	 86.3	–	106.1	 5.11	
RMB005	 475.218	!	334.200	 83.9	–	114.8	 11.5	
DQ	 418.103	!	372.200	 88.9	–	109.8	 15.5	
	
Table	 8-14:	 Accuracy	 and	 precision	 from	 quality	 control	 samples	 prepared	 at	 high,	
medium	and	low	concentration.	
Compound	 Transition	 Accuracy	(%)	 CV	(%)	
WHN012	 490.312	!	224.200	 89.2	–	102.9	 14.8	
AD01	 341.000	!	297.300	 87.4	–	109.8	 12.2	
PhX6	 395.219	!	351.400	 99.1	–	110.1	 10.2	
DpNEt	 286.165	!	241.300	 85.1	–	106.5	 11.7	
RMB005	 475.218	!	334.200	 94.5	–	106.5	 12.4	




























injection	 solution	 containing	 the	 ISTD	and	analysed	with	LC/MS-MS.	The	 stability	was	





















WHN012	 92.6		 98.1	 96.6	 91.4	
PhX6	 96.1		 86.8	 84.6	 83.9	
AD01	 85.2		 94.4	 95.4	 99.7	
DpNEt	 96.5		 88.4	 91.9	 93.7	
RMB005	 95.9		 99.6	 89.9	 81.6	
RMB059	 106.0		 88.5	 98.3	 97.4	
RMB060	 73.8		 94.4	 92.1	 92.6	
DQ	 85.1	 97.2	 99.1	 87.1	










to	enzymes	present	 in	 the	blood	and	plasma.243	 	Awareness	of	stability	of	 the	analytes	
during	 these	 processes	 is	 crucial	 for	 the	 reliability	 and	 reproducibility	 of	 data.	 	 Blank	
matrix	 (mouse	 plasma	 or	 whole	 blood)	 spiked	 with	 analytes	 at	 high	 and	 low	







Highc	 Lowc	 Highc		 Lowc	
WHN012	 111.0	 101.0	 111.6	 103.0	
PhX6	 92.4	 86.2	 88.8	 88.7	
AD01	 92.6	 85.1	 87.1	 93.3	
DpNEt	 96.5	 90.1	 91.4	 88.1	
RMB005	 92.1	 83.1	 81.6	 84.3	
RMB059	 37.8	 25.9	 nd	 nd	
RMB060	 46.3	 49.8	 nd	 nd	
DQ	 104.7	 104.8	 97.8	 99.1	
avalues	 presented	 as	 percentages	 compared	 to	 that	 obtained	 from	 freshly	 prepared	
reference	sample;	bvalues	reported	had	a	%CV	less	than	15%;	chigh,	1000	ng/mL;	low,	25	
ng/mL.	Samples	were	analysed	in	triplicate	
All	 the	 investigated	 compounds	 had	 acceptable	 stability	 in	 their	 respective	 matrices	
(mouse	whole	blood	or	plasma),	except	for	RMB059	and	RMB060.	This	was	also	reflected	









The	 stability	 of	 compounds	 in	 their	 respective	 solutions	 used	 for	 both	 oral	 and	
intravenous	 administration	 to	 animals	 was	 tested	 over	 the	 course	 of	 30	 minutes,	 as	















avalues	 presented	 as	 percentages	 compared	 to	 that	 obtained	 from	 freshly	 prepared	
reference	sample,	CV	values	were	below	15%	 for	all	values.	Samples	were	analysed	 in	
triplicate		
WHN012,	 PhX6,	 AD01	 and	 RMB005	 presented	 acceptable	 stability	 (i.e.	 <	 20%	
degradation)	in	both	the	oral	and	intravenous	formulations.	Oral	formulations	of	DpNEt,	














the	 concentration	 profile	 of	 the	 compounds.	 No	 contamination	 of	 test	 compound	 or	

































































































assessed	 using	 the	 Matuszewski	 method.	 The	 method	 utilizes	 a	 calibration	 range	 to	







methods	 described	 in	 Section	 4.3.7.	 No	 matrix	 effects	 were	 observed	 for	 any	 of	 the	














WHN012	 3.5	 82	 96	 89	(11.3)	
PhX6	 3.9	 94	 97	 95	(2.30)	
AD01	 3.2	 113	 99	 106	(8.60)	
DpNEt	 3.3	 109	 115	 112	(3.90)	
RMB005	 1.9	 62	 62	 62	(0.10)	
DQ	 1.4	 65	 55	 60	(11.1)	
Samples	were	analysed	in	triplicate.	
	
